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Abstract
I biomarcatori molecolari, ottenuti attraverso lŠutilizzo di piattaforme high-throughput
sequencing, costituiscono le basi della medicina personalizzata di nuova generazione.
Nonostante un decennio di sforzi e di investimenti, il numero di biomarcatori validi
a livello clinico rimane modesto. La natura di Şbig-dataŤ dei dati omici infatti ha
introdotto nuove sĄde che richiedono un miglioramento sia degli strumenti di analisi
che di quelli di esplorazione dei risultati. In questa tesi vengono proposti due temi
centrali, entrambi volti al miglioramento delle metodologie statistiche e computazionali
nellŠambito dellŠindividuazione di Ąrme molecolari.
Il primo lavoro si sviluppa attorno allŠidentiĄcazione di miRNA su siero in pazienti
afetti da carcinoma ovarico impiegabili a livello diagnostico. In particolare si propon-
gono delle linee guida per il processo di analisi e una normalizzazione ad-hoc per dati
di microarray da utilizzarsi nel contesto di molecole circolanti.
Nel secondo lavoro si presenta un nuovo approccio basato sui modelli graĄci Gaus-
siani per lŠidentiĄcazione di Ąrme molecolari funzionali. Il metodo proposto è in grado di
esplorare le informazioni contenute nei pathway biologici e di evidenziare la potenziale
origine del comportamento diferenziale tra due condizioni sperimentali.

Abstract
Molecular biomarkers, derived from high-throughput technologies, are the foundations
of the Şnext-generationŤ precision medicine. Despite a decade of intense eforts and
investments, the number of clinically valid biomarkers is modest. Indeed, the Şbig-dataŤ
nature of omics data provides new challenges that require an improvement in the
strategies of data analysis and interpretation.
In this thesis, two themes are proposed, both aimed at improving the statistical and
computational methodology in the Ąeld of signatures discovery. The Ąrst work aim at
identifying serum miRNAs to be used as diagnostic biomarkers associated with ovarian
cancer. In particular, a guideline and an ad-hoc microarray normalization strategy for
the analysis of circulating miRNAs is proposed.
In the second work, a new approach for the identiĄcation of functional molecular
signatures based on Gaussian graphical models is presented. The model can explore
the topological information contained in the biological pathways and highlight the
potential sources of diferential behaviors in two experimental conditions.
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Chapter 1
OVERVIEW
In the last two decades, high-throughput technologies have allowed an unprecedented
vision of molecular biological systems. The research Ąelds that are involved in obtaining
and understanding these measures - such as genomics, transcriptomics, and proteomics
- are commonly aggregated in the so-called ŞomicsŤ sciences.
Given a molecular measurement, a natural objective is the development of statisti-
cal models that use these measures to predict the clinical outcome of interest, such
as disease state, survival time, response to therapy. Often, patients with the same
symptoms and signs of cancer have diferent results, or patients subject to an identical
medical treatment have diferent reactions to the toxicity of a drug. The improvement
of prognosis and diagnosis regardless of the approach and the data chosen is the goal
of Şprecision medicineŤ.
Precision medicine, in its more recent sense, is based on Ąnding a set of signature
molecules. A molecular signature is thus deĄned as a set of biomolecular features (e.g.,
DNA variations, DNA copy number, mRNAs, proteins and metabolite abundances)
together with a predeĄned computational procedure that is able to predict a phenotype
of clinical interest.
Biomarkers are the foundations of precision medicine, and they can be grouped on
the basis of a variety of characteristics. For example, according to the purpose, they
can be correlational (i.e., only associated with the disease) or functional (i.e., they
have an identiĄed mechanism of action related to disease). In general, they can be
measured and used individually or in groups to infer the risk, diagnosis, prognosis, or
therapeutic response. ClassiĄcation may also depend on the type of molecule used.
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DNA, RNA, protein metabolites can all function as biomarkers.
The statistical model used for biomarkers identiĄcation and phenotype prediction,
independent of the univariate or multivariate setting, can be divided into two major
categories of approaches: i) evidence-based approaches (EBAs) and ii) knowledge-
based approaches (KBAs). EBAs are commonly associated with hypothesis-generating
paradigms and allow interrogating essentially all the collected data by providing the full
spectrum of possible associations between genotype and phenotype. In contrast, KBAs
try to infuse expert knowledge into omics data analysis through hypothesis-testing
paradigms. The Ąrst category is frequently used in the screening phase, where the goal
is the diagnosis and/or the prognosis, without any particular interest in functionality.
Whereas, the second class is more targeted to providing mechanistic evidence, rather
than the prediction of a phenotype. Although this diferent application, the EBAs,
and KBAs are not mutually exclusive, but they must be thought of as complementary
tools to facilitate and complement various goals.
Precision medicine in the last decade has accumulated a long list of terms with
similar meanings, including personalized medicine, P4 medicine, genomic medicine,
predictive medicine, and individual medicine. Although its evolution, the overall ap-
proach to the development of signatures has not changed considerably. Indeed, despite
a decade of intense eforts and a substantial investment in labor and funds, the number
of clinically valid biomarkers approved by FDA (Food and Drug Administration) are
modest, creating in the scientiĄc community a certain mistrust for the ŞbiomarkerŤ term.
The success of molecular signature discovery has mainly been hampered by several
factors that characterize all Şbig dataŤ disciplines. The Ąrst di culty can be attributed
to the low number of samples collected in omics experiments, compared to the number
of measured molecules. In fact, most biomarkers are identiĄed at the tissue-level and
therefore require invasive procedures such as biopsy, slowing down the possibility of
expanding existing cohorts. Although tissue-level studies are often crucial in recognizing
a mechanistic link between biomarkers and carcinogenesis, they are not practical for
assessing cancer risk or monitor response to treatment in the clinic of large populations
over time.
Also, the heterogeneous nature of omics data presents a new challenge that requires
a deep understanding of the underlying biological mechanisms and the algorithms to
perform data integration and interpretation. Thus, it becomes crucial to understand
3the advantages and disadvantages of diferent platforms to carry out explorations and
to draw inference models that can decipher and translate the molecular mechanisms
expressed by molecular proĄles, in an automatic and functional way.
In this thesis, two central themes are proposed, both intended to contribute to the
improvement of statistical and computational methodology in the Ąeld of signature
discovering.
In the Ąrst part (Part I), I present a study aimed at identifying circulating miR-
NAs to be used as diagnostic biomarkers associated with ovarian cancer, based on an
evidence-based approach. In particular, a reĄnement of the normalization strategy,
speciĄcally designed to adapt to the properties of circulating molecules, is proposed.
Particular attention has also been paid to the experimental design to ensure i) consistent
homogeneity of the samples using clinical information and ii) reproducibility of the
obtained results, using three proĄling technologies and two independent cohorts.
In the second part (Part II), a new knowledge-based approach to identify functional
molecular signatures is proposed . In particular, an innovative perspective is used to
exploit the topological information contained in biological pathways through Gaussian
graphical models, moving from marginal-based to conditional-based approach. Through
this model, it is possible to zoom on the potential sources of the diferent behaviors of
two experimental conditions, identify its causes and translate the results into biological
hypotheses. The natural application of this model is aimed at clarifying carcinogenesis
processes and developing therapeutic targets.

Part I
Circulating miRNA landscape
identifies miR-1246 as promising
biomarker in high-grade serous
ovarian carcinoma

Chapter 2
INTRODUCTION
2.1 High-Grade Serous Ovarian Carcinoma
Ovarian Cancer (OC) is the seventh most diagnosed tumor among women and the
most lethal gynecology malignancy. Annually, 239.000 new cases and 152.000 deaths
are estimated worldwide. The highest rate is recorded in East and Central Europe [30].
The majority of ovarian cancer - benign and malignant forms - are of epithelial origin
(90%), whereas fewer develop from other cell types, such as sex-cord stromal (5-6%),
germ cell (2-3%) or mixed cell-type tumors [60]. Within the most common type of
ovarian cancer - the epithelial ovarian cancer (EOC) - Ąve main subtypes are identiĄed:
high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%) and
low-grade serous (<5%) [64]. These histotypes reĆect the strong heterogeneity of the
EOC regarding cellular origin, pathogenesis, molecular alterations, gene expressions,
and prognosis, as to be considered essentially distinct disease.
The most common histological EOC, high-grade ovarian cancer (HGSOC) is char-
acterized by a high aggressiveness and rapid development, with a Ąve-year survival
rate after diagnosis of less than 30%. In fact, in 90% of cases, despite an aggressive
surgery and early chemotherapy, patients develop resistance to platinum agents and
die from an incurable disease. Indeed, because of its asymptomatic nature, 70% of
HGSOC are diagnosed in the advanced stage when the neoplasm is difused into the
peritoneum (stage III) and to distant organs organ (stage IV).
The lack of therapeutic measures that can eiciently improve survival also depends
on the fact that the precursor lesion and the pathogenesis of the disease are still being
discussed within the scientiĄc community. Although, in the last decade, a growing body
of evidence suggests that the majority of EOC could develop from other gynecological
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tissues [76] - involving only overseas ovary - morphological and genetic studies do
not have a clear pattern of progression. In particular, HGSOCs could originate from
the epithelium of the Ąbrial end of the fallopian tube. At present, the most efective
strategy to reduce mortality in HGSOC patients is the complete surgical debulking of
ovaries and fallopian tubes in women carrying germline BRCA1/BRCA2 mutations or
with a strong family history of breast and/or ovarian cancer.
From this overview, it emerges the importance of optimizing clinical outcomes
through early diagnosis detection in order to limit invasive surgeries and to achieve
survival improvement.
2.2 Diagnosis and screening
The often asymptomatic nature of primary lesions, along with the lack of adequate
screening and diagnosis technique, make the discovery of HGSOC in early stages of
the disease, an infrequent event.
At present, the serum Carbohydrate Antigen 125 (CA-125), in combination with
transvaginal ultrasound, is the most common biomarker used for the diagnosis of
the HGSOC. However, CA-125 cannot be adequately characterized as a screening
test because of the high incidence of false positives [100] among benign gynecological
conditions in premenopausal women (such as endometriosis).
The inefectiveness of CA-125 screening properties has been illustrated in an
extensive multicenter prospective study, called PLCO (Prostate, Lung, Colorectal and
Ovarian Cancer Screening) [112], where the predictive value of CA-125 resulted in
less than 4%. In general, at the diagnostic level, the sensitivity of CA-125 in the
distinction between benign and malignant mass varies between 61% and 90%, while the
speciĄcity ranges between 35% and 91%. The wide variation is due to diferent inclusion
criteria for premenopausal women in diverse studies [74]. To endorse these Ąndings, a
more recent UK Cancer Cancer trial (UKCTOCS) [43] analyzed more than 200.000
post-menopausal women to assess the predictive capacity of CA-125 in combination
with ultrasound scanning. The results showed a modest reduction in mortality, for
an estimated 20% after 14 years, where 50% of cases were detected by multimodal
screening or ultrasound alone.
A mention should be made for another diagnostic serum marker that has emerged in
recent years, that is the Human Epididymis protein 4 (HE4) [26]. Based on encouraging
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results, Moore et al. [69] developed the Risk of Ovarian Malignancy Algorithm (ROMA)
based on a scoring system that combines levels of HE4 and CA-125. This algorithm
has proved useful in detecting the EOC and is becoming increasingly widespread in
clinical practice for the discrimination of benign masses.
However, in the last two decades, none of these predictors impacted - in a consistent
way - mortality rate reduction of this disease, because of their limited sensitivity and
speciĄcity. In fact, based on current results, widespread screening is not yet justiĄed
using the diagnostic methods presented.
In this scenario, technological advances in high-throughput technologies could
improve the discovery of new screening and diagnosis biomarkers, aimed at deĄning
the individual risk of contracting a speciĄc disease. One of the most promising research
Ąelds relies on microRNA expression proĄles (miRNA) in liquid biopsies, such as serum
and plasma.
The choice of circulating molecules is motivated mainly by the two central limits
that distinguish the tissue samples. First, tissue samples are di cult to acquire during
patient follow-up and require invasive procedures, so the evaluation of their role in
longitudinal analysis is limited. Secondly, since HGSOC is a systemic disease, the
molecular portraits obtained in the ovary do not necessarily reĆect those obtained from
synchronous lesions in other anatomic sites [77].
Liquid biopsies are becoming a new resource for developing new biomarkers for
diagnostic purposes
2.3 Circulating miRNAs in cancer
MicroRNAs are highly conserved single-stranded small RNA molecules that play a key
role in post-transcriptional regulation of genes [2]. These small RNA molecules bind to
the 3 ŠUTR region of their target mRNAs, inducing post-transcriptional regulation of
the gene by inhibiting its translation or degradation [4].
Recent studies have shown that miRNAs can move (encapsulated in exons and/or
bound to lipoproteins) from tumor tissue to circulation, following apoptotic and necrotic
cell death or as active release [101]. As a result, these molecules can be found in a
variety of body Ćuids (such as blood, serum, plasma, urine, saliva, seminal Ćuid and
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pleural efusion) [18] in a stable form - protected by endogenous RNAs - thus making
miRNA levels circulating well suited for minimally invasive patient analysis [66].
Although the expression levels of circulating miRNAs reĆect the cumulative efects
of several underlying pathways, not yet fully clariĄed [17], independent studies have
shown, in the context of malignancy, a potential as molecular instruments for diagnosis,
prognosis, and choice of treatment for various cancers.
One of the Ąrst studies that demonstrated their involvement in cancer patients was
by Lawrie et al. [55]. The authors pointed out that the levels of three microRNAs
(miR-155, miR210, and miR-21 ) were signiĄcantly higher in the serum of patients with
large B-cell lymphoma, and among them, miR-21 was associated with relapsed free
survival of patients. Subsequently, serum miRNAs were tested as biomarkers for disease
monitoring in prostate cancer, and for early diagnosis of both lungs and colorectal
carcinomas. Besides, similar studies have been performed in many types of cancer
including gastric, breast and ovarian cancer [111, 89, 72]. Currently, the miR-test,
based on a 13-miRNA serum signature, is one of the most promising instruments for
screening lung cancer in high-risk individuals [68].
2.4 Motivation problem
In the last decade, even in ovarian cancer, several circulating miRNAs have been
identiĄed as biomarkers with early diagnosis implications in association with clinical
pathology and prognosis (Table 2.1). However, the assessment of the speciĄcity and
reproducibility of the individual studies reported suggests that the realization of this
promise for EOC remains work in progress. Although it is impossible to directly
compare the results of all studies - given the distinct questions and the small miRNAs
panel they have focused on - there is a general inconsistency due to the large variety of
methodological parameters that compromise evaluation.
Several are the pre-analytic and analytic aspects that may interfere with the accu-
rate quantiĄcation of the proposed circulating miRNAs biomarkers, such as individual
factors, detection platforms, independent validation and data analysis [98]. The lack
of overlap between studies suggests, therefore, the urgency of further investigations on
well-characterized patients with ovarian cancer and a larger panel of miRNAs, that could
consistently address all technical challenges afecting the analysis of miRNA circulating.
2.4
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otivation
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Authors Years
Type of
tissue
Histol-
ogy
Control Up-regulated Down-regulated
Discovery
platform
Taylor et al. [95] 2008
Serum
exosome
Serous
Benign ovarian
tumor
miR-21, miR-141,
miR-200a,b,c, miR-203,
miR-205, miR-214
-
Custom microRNA
arrays
Resnick et al. [81] 2009 Serum EOC Healthy control
miR-21, miR-29a, miR-92,
miR-93, miR-126
miR-127, miR-155 miR-99b
TaqMan array
RT-qPCR
Hausler et al. [37] 2010
Whole
blood
EOC Healthy control miR-30c1
miR-342-3p, miR-181a,
miR-450-p
Geniom Biochip
Kan et al. [46] 2012 Serum HGSC
HOSE/healthy
control
miR-200a,b,c - TaqMan assays
Chung et al. [15] 2013 Serum Serous Healthy control -
miR-132, miR-26a, let-7b,
miR-145
Microarray RT-qPCR
Zheng et al. [110] 2013 Plasma EOC Healthy control miR-205 let-7f
TaqMan low-density
array RT-qPCR
Xu et al. [108] 2013 Serum EOC Healthy control miR-21 - RT-qPCR
Hong et al. [38] 2013 Serum EOC Healthy control miR-221 - RT-qPCR
Ji et al. [45] 2014 Serum EOC
Healthy control /
benign ovarian
tumors
miR-22, miR-93 - Solexa sequencing
Shapira et al. [88] 2014 Plasma Serous
Healthy control /
benign ovarian
tumors
-
miR-106a, miR-126,
miR-146-a, miR-150,
miR-16, miR-17, miR-19b,
miR-20a, miR-223, miR-24,
miR-92a
TaqMan Open Array
MicroRNA
Langhe et al. [53] 2015 Serum Serous
Benign ovarian
tumor
-
let-7i-5p,miR-122,
miR-152-5p, miR-25-3p
Exiqon panel
RT-qPCR
Gao et al. [32] 2015 Serum EOC Healthy control miR-200c, miR-141 - RT-qPCR
Zuberi et al. [114] 2015 Serum EOC Healthy control miR-200a,b,c - RT-qPCR
Zuberi et al. [113] 2016 Serum EOC Healthy control - miR-199a RT-qPCR
Meng et al. [65] 2016
Serum
exosomes
EOC Healthy control miR-373, miR-200a,b,c - TaqMan assay
T
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For this reason, we propose to measure miRNA expression levels in HGSOC patients
on microarray technology, to select the most promising microRNAs among the largest
set of possible candidates sourced from miRNome. We collected serum of 168 HGSOC
patients and 65 healthy controls, by two independent collections. We divided them
into a training set, to identify candidate biomarkers, and validation set, to conĄrm
their reproducibility. During the second phase, we used RT-PCR and ddPCR, in order
to improve the accuracy and reduce the bias due to the technology used. Finally, we
proposed an innovative statistical approach to normalize microarray data, designed
to best Ąt the characteristics of the circulating molecules in the high-throughput context.
In the following chapters, all the pre-analytical and analytical aspects of the selection
and analysis process are described in detail and the comments on the obtained results -
with particular emphasis on statistical aspects - are presented.
Chapter 3
MATERIALS and METHODS
3.1 Serum samples collection
The following sections describe the optimized protocols used, including collection,
handling, storage, miRNAs extraction and hemolysis monitoring of serum samples.
In particular, the cohort of serum samples consists of a total of 233 patients, collected
by two independent Italian collections, between 2003 and 2013. The Ąrst, collected
at the Department of Obstetrics and Gynecology of ASST Spedali Civili (University
of Brescia, Brescia - Italy), consists of 110 patients with stage III-IV HGSOC and
52 healthy individuals of comparable age. The second, collected at the Oncological
Division of Oncology of the A.Gemelli Clinical Hospital (Catholic University, Rome
- Italy), is made up of 58 specimens of patients with HGSOC and 13 samples of
comparable healthy individuals.
3.1.1 Sample
7.5 ml of blood were collected in S-Monovette with clot activator (Sarstedt AG & Co.,
Numbrecht, Germany) and centrifuged after half an hour at 3000 rpm for 10 minutes
at room temperature. The serum was then aliquoted and stored at −80◦C within an
hour. Free hemoglobin concentration was analyzed using miR-451a and miR-23a-3p
expression ratio to exclude hemolyzed samples from downstream analyses [53]. All
samples showed a very homogeneous level of expression ratio, markedly below level 5,
demonstrating the absence of hemolysis in the collected samples.
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Species RNA Oligo Sequence
Kaposi sarcoma associ-
ated herpesvirus
kshv-miR-K12-2 5’-rGrUrC rCrGrGrGrUrCrGrArU rCrUrG-3’
Human Citomegalovirus hcmv-miR-UL112 5’-rCrGrG rUrGrArGrArUrCrCrArGrGrC rU-3’
Epstein-Barr virus ebv-miR-BART8 5’-rCrGrG rUrUrUrCrCrUrArGrArUrUrGrUrArC rArG-3’
C.elegans cel-miR-39-5p 5’-AGCUGAUUUCGUCUUGGUAAUA-3’
C.elegans cel-miR-54-5p 5’-AGGAUAUGAGACGACGAGAACA-3’
C.elegans cel-miR-238-3p 5’-UUUGUACUCCGAUGCCAUUCAGA-3’
Arabidopsis thaliana ath-miR-160a 5’-UGCCUGGCUCCCUGUAUGCCA-3’
Arabidopsis thaliana ath-miR-171b 5’-UUGAGCCGUGCCAAUAUCACG-3’
Arabidopsis thaliana ath-miR-416 5’-GGUUCGUACGUACACUGUUCA-3’
Arabidopsis thaliana ath-miR771 5’-UGAGCCUCUGUGGUAGCCCUCA-3’
Table 3.1 Ten synthetic spike-in RNA oligo sequences
3.1.2 Total RNA extraction
Total RNA was extracted from 200µl of serum using miRNeasy Mini kit (Qiagen, Milan
Italy). In particular, serum samples were thawed in ice, then 1 ml of QIAzol Lysis
Reagent (Qiagen) was added to the samples, and they were kept at room temperature
for 5 minutes. Ten synthetic spike-in RNA oligos, without sequence homology to
known human miRNAs, were added to samples to control for variations during the
preparation of total RNA and subsequent steps (Table 3.1). The spike-in RNA oligos
were introduced in serum samples as a mixture of 12.5 fmol in a total volume of 2.5
µl. All the last steps of puriĄcation were performed following the manufacturerŠs
instructions. RNA was eluted from spin columns in 35 µl of nuclease-free water, and
15 µl were used for miRNA expression proĄling.
3.1.3 miRNA profiling by microarray
We used the commercially available G4872A-046064 human miRNA Microarray (Agilent
Technologies), customized with probes for the detection of speciĄc RNA spike-in oligos.
For circulating miRNA proĄle, we hybridized Ąxed volume of eluted total RNA,
derived from Ąxed serum volumes, for all samples tested. The arrays were washed
and scanned with a laser confocal scanner (G2565BA, Agilent Technologies) according
to the manufacturerŠs instructions. miRNA microarrays underwent standard post-
hybridization processing, and the intensities of Ćuorescence were calculated by Feature
Extraction software version 11 (Agilent Technologies).
3.2 Tissue samples collection 15
3.1.4 cDNA synthesis and Real-Time PCR
Real-Time-reverse transcription PCR (RT- qPCR) was performed starting from 5 ml
of total RNA, puriĄed and reverse transcribed into cDNA, following manufacturerŠs
instructions (miScript Reverse Transcription Kit, Qiagen). We used a Ąxed volume of
eluted RNA sample as input for RT-qPCR, rather than using a Ąxed quantity of input
RNA [50]. Two microliters of cDNA were used for RT-qPCR experiments in triplicate
using Rotor-Gene Thermal Cycler (Qiagen). Operations were run in triplicate and
plates were prepared by automatic liquid handling station in a Ąnal volume of 10 ml
(QiaAgility).
3.1.5 Digital droplet PCR
Each EvaGreen ampliĄcation mixture (20 ml) was loaded into a disposable droplet
generator cartridge (Bio-Rad) and mixed with 70 ml of droplet generator oil into the
QX200 droplet generator (Bio-Rad), thus portioning each sample into 20,000 nL-sized
droplets. EmulsiĄed samples were then transferred into a 96-well PCR plate to perform
PCR, using a conventional thermal cycle.
The cycling steps were set as follow: 95◦C for 5min,(95◦C for 30 min, 58◦C for
1min) 40 cycles, 4◦C for 5 min, 90◦ C for 5 min and inĄnite 4◦C holding. The PCR
plate was then loaded into the QX200 droplet reader (Bio-Rad) for sample automated
analysis. A no template control (no cDNA in PCR) and a negative control for each
reverse transcription reaction (RT-neg) were included in every assay run.
3.2 Tissue samples collection
The following sections describe the optimized protocols used, including collection,
handling, storage and miRNAs extraction of tissue samples.
In particular, the cohort of tissue samples consists of 76 out of 110 HGSOC patients
enrolled at the Department of Obstetrics and Gynecology of ASST Spedali Civili
(University of Brescia, Brescia - Italy) (see Section 3.1). As controls, 28 samples of
normal ovarian and fallopian tubes are used from patients undergoing a hysterectomy
and bilateral salpingo-oophorectomy for benign pathologies, in the same institution.
Control samples were collected between 2011 and 2013.
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3.2.1 Sample
Neoplastic tissue specimens were sharp-dissected and frozen in liquid nitrogen within
30 minutes of debulking surgery. For each sample, a specular hematoxylin-eosin
section was reviewed by a staf pathologist to check for epithelial purity and only
samples containing at least 70% tumor epithelial cells were used for the following RNA
extraction.
Normal luminal fallopian tube epithelial cells and normal ovarian surface epithelial
(HOSE) cells were collected by scraping in 1ml of physiological saline solution immedi-
ately after surgery and centrifuged at 1000 rpm for 10 minutes. The cell pellet was
then resuspended in 200 µl of TRIzol Reagent (Life Technologies, Carlsbad, CA, USA)
and stored at -80◦C. All the normal samples were veriĄed to be free of any neoplastic
pathology before using for total RNA extraction.
3.2.2 Total RNA extraction
Total RNA from tissue samples was isolated using TRIZOL reagent (Life Technologies)
and further puriĄed using RNeasy MiniElute Cleanup kit (Qiagen), with a modiĄed
protocol for co-puriĄcation of small RNAs according to the manufacturerŠs instructions.
RNA concentration and 260/280 absorbance ratio (A260/280) were measured with
InĄnite M200 spectrophotometer (TECAN). RNA integrity was assessed with RNA
6000 Nano LabChip kit using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA). RNA integrity number (RIN), generated with Agilent 2100 Expert
software, was superior to 8 for all RNA samples.
Only samples with good RNA yield and no RNA degradation were retained for
further experiments. RNA samples were diluted at 75 ng/mul and 50 ng/µl for gene
expression and miRNA expression proĄling, respectively.
3.2.3 miRNA profiling by microarray
For tissue miRNA proĄling, 100 ng of RNA, enriched in miRNA fraction, were Cyanine
3-pCp labeled and hybridized to the commercially available G4871A human miRNA Mi-
croarray, using a miRNA labeling and hybridization kit according to the manufacturerŠs
instructions (Agilent Technologies).
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3.3 Statistical analysis
All the analyses were made using statistical software R (version 3.3.1) [96] and several
libraries, freely available at CRAN and Bioconductor repositories. In this section,
we provide some essential notions and relevant references about the methods used to
perform the analysis.
3.3.1 Cyclic lowess
Cyclic locally weighted smoothed spline (cyclic lowess) method was used to normalize
microarray data, both for serum and tissue sample.
Lowess [16] is a normalization method for microarray data - initially conceived for
dual channel data - that combines multiple regression models into a k-nearest-neighbor-
based meta-model. It is based on the ŞM versus AŤ (MA) plot, where M represents
the diference between the log expression values of one observation in two experiments,
and A is the average of the log expression of these values. The MA plot for normalized
data would show a points cloud scattered around the M = 0 axis.
The cyclic lowess normalizes two samples at a time by applying a correction factor
obtained by estimating locally weighted polynomial regression, based on the points
trend of the MA plot. A loop - or iteration - of the algorithm consists of performing
this pairwise normalization on all distinct pairs of samples. For a complete outline of
the algorithm, refer to Cleveland et al. [16].
A drawback of cyclic lowess is the amount of time required to normalize a set
of data, in fact, the computational time grows exponentially with the number of
samples. For this reason, Bolstad et al. [8] propose a fast version - that grows linearly
- where each sample is normalized with respect to a reference, which is constructed
as the average of all samples. This version of the algorithm is implemented in the
normalizeCyclicLoess function of the R limma package [82].
In general, the lowess algorithm requires Ąve parameters: i) the polynomial order;
ii) the number of algorithmic iterations; iii) the weight function; iv) the span of the
loess smoothing window, and iv) the weight of each probe. While for the Ąrst three
parameters there are standard choices suggested by the literature, the last two are often
arbitrarily chosen. In fact, the way they are deĄned is highly subject to interpretation
depending on the actual data. In the next chapter (Section 4.3.2) we will describe the
way we set these parameters to deal with circulating miRNAs.
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3.3.2 eBayes test
Empirical Bayes test (eBayes) [91] has been used in testing for diferential expression
microarray data, for both the serum and tissue sample.
Although t-test is a popular choice for detecting diferential expression genes (DEGs)
in microarray experiments, is documented to not work well with low expression levels
and outliers. For these reasons, a class of moderate t-test statistics able to address
the problem of variance instability has been proposed. In particular, eBayes shrinks
the probe-wise sample variance towards a common value: the obtained variance for
each gene is a compromise between the gene-wise estimator - derived from the data for
that gene alone - and the global variation across all genes - estimated by pooling the
ensemble of all the genes [91].
The limma package [82] includes a robust estimation strategy for the shrinkage
parameters of the model, and it is implemented in the eBayes function. This function
has been used to rank genes in order of evidence for diferential expression.
3.3.3 ROC curve
The Receiver Operating Characteristic (ROC) curves have been used to illustrate the
diagnostic capacity of microRNA proĄles as binaries classiĄer.
A ROC curve is created by representing on the y-axis the true positive rate
(sensitivity) and on the x-axis the false positive rate (1-specificity), across a series of
thresholds. The random choice is represented by the bisection between the Ąrst and
third quadrants.
The total Area Under the Curve (AUC) is a single value used to summarize the
overall performance of the test. In our case, the larger the AUC, the better is the
ability of one microRNA to correctly distinguish afected and unafected subjects. It
should be stressed that two identical AUC, may have very diferent ROC curve. An
asymptotically exact method to evaluate the uncertainty of an AUC has been proposed
by Delong et al. [20].
The optimal cut-of is obtained by Ąrst calculating the distance of each observed
cut-of point from the point (0.1) (i.e., the perfect classiĄer), and Ąnally choosing the
threshold that minimizes this distance. This criterion gives equal weight to sensitivity
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and speciĄcity and imposes no ethical, cost, and no prevalence constraints.
The package pRoc [83] contains a collection of tools for calculating, visualizing
and comparing receiver operating characteristic curves. In particular, we used roc
and auc functions.
3.3.4 Hierarchical clustering
To evaluate the discriminatory capacity of diferential expressed microRNAs - between
control and case - we used an unsupervised learning method. Precisely, we used a
distance-based hierarchical clustering approach.
The Ąrst step in any method of cluster analysis consists of deĄning a rule of sim-
ilarity between two objects, in this case, the samples of our experiment. The most
common choice is to measure the pairwise Euclidean distance, among all possible cou-
ples of samples, and record these measurements in a distance matrix. The hierarchical
clustering algorithm begins by assigning each sample to a separate cluster and then
iteratively proceeds to merge the two most similar clusters at each step, as long as a
single cluster is obtained. At each stage distances between clusters are recomputed by
the Lance-Williams dissimilarity update formula.
In particular, the dist function was used to calculate the distance matrix, while
for the clustering analysis the hclust function was used, with a complete method.
Both are implemented in the stats R package [96].

Chapter 4
ANALYSIS and RESULTS
4.1 Workflow
The focus of this work is the detection of the levels of circulating miRNAs in sera
from patients with HGSOC as a Ąrst step in the evaluation process of their role as
diagnostic biomarkers.
The workĆow of the circulating miRNAs analysis process is divided essentially into
three phases (Figure 4.1):
(i) the cohort selection phase (both for training and validation set) (Section 4.2);
(ii) the explorative discovery phase, using microarray data (Section 4.3);
(iii) the candidates selection and validation phase, using RT-qPCR (Section 4.4).
In particular, the principal source of analytical variation in the procedure is derived
from the normalization strategies related to the diferent used technologies, corrected
adopting ad hoc procedures, as shown in Section 4.3.2 (for microarray data) and Section
4.4.2 (for RT-PCR data).
In the following, we present the obtained results. Moreover, we discuss in detail the
pre-analytical and analytical aspects of the study which, in our opinion, represents an
improvement compared to previous studies concerning this disease, and can be used as
a guideline for future studies aimed at the same purpose.
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Fig. 4.1 Flowchart summarizing the different steps and the main results of the circulating
miRNAs analysis for the HGSOC datasets.
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4.2 Cohort selection
The main variables that may have profound implications for the accurate detection of
biomarkers are those related to intrinsic inter-individual variability [98].
Facing circulating miRNAs as ovarian cancer biomarker molecules, the Ąrst source of
variability to be considered is related to the tumor itself. In fact, the literature suggests
that each EOC histotypes should be viewed as a distinct disease, as indicated by their
diferences in epidemiological and genetic risk factors, precursor lesions, patterns of
spread, molecular events during oncogenesis, response to chemotherapy and prognosis
[78]. So, we focused exclusively on HGSOC in patients, which is the most frequent and
aggressive subtype.
Moreover, since many studies show how individual variability can contribute to
afecting miRNA levels, we have created a cohort as homogeneous as possible, con-
sidering various clinical-pathological features such as age, FIGO stage, ascites, and
metastasis. Refer to Supplementary Materials by Todeschini et al. [99] for a complete
view of the considered variables.
In particular, serum samples were collected at the time of diagnosis before each
treatment, and come from two independent Italian tumor serum collections (training
and validation set), as described in Section 3.1. In contrast, tissue samples were
collected at the Ąrst surgery (Section 3.2). The training set consists of 162 samples
(110 HGSOC, 68% - 52 controls, 32%), while the validation set consists of 71 samples
(58 cases, 82% - 13 control, 18%).
All patients were staged according to FIGO (Federation International of Gynecology
and Obstetrics) guidelines as stage III-IV stage [79], with high-grade serous histological
type. The median age at diagnosis was 61 and 58 years for the training and the
validation set, respectively. The vast majority of women were in postmenopausal status
(77% and 71% for the training and the validation set, respectively). Some patients
showed the presence of ascites (82% training set and 54% validation set, respectively)
and lymph node metastasis (39% for the training set and 36% for the validation set).
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4.3 Discovery phase
To identify the entire repertoire of known miRNAs - sourced from miRBase version 19
- expressed in patients with stage III-IV HGSOC, a microarray proĄling was performed
in the training set. We chose the Agilent system as it emerged as the one of those
obtaining the highest performances among hybridization-based methods [11], and it
is probably the most commonly used. Accurate measurement of circulating miRNAs,
through high-throughput technologies, poses diferent challenges due to both their
short lengths and the low abundance of these molecules in body Ćuids.
Here, we focus on three aspects: i) Ąltering (Section 4.3.1), ii) normalization (Section
4.3.2) and iii) diferential expression analysis (Section 4.3.3).
4.3.1 Quality control and filtering
The Ąrst step in analyzing microarray data is to Ąlter microRNAs that are not expressed.
The Agilent system contains a Ćag for each spot that states whether the molecule is
expressed or indeterminate (gisPosandSig Ćag) and can be used to select only miRNAs
with stable expression values within an array.
Serum raw microarray data comprised an initial number of 1361 miRNAs (included
controls and spikes, see Section 3.1.2) repeated 40 times. The expression of these
40 replicates per miRNA has been used as technical replicates and quality control.
SpeciĄcally, within each experiment, we selected only miRNAs with at least 20% of
good quality measures among the 40 replicates. Otherwise, they were considered NA
(not available). Then, the second Ąlter was applied to the arrays. SpeciĄcally, we
selected only miRNAs with at least 75% of good quality measures (not NA) across
samples. After these Ąltering steps, we remain with 638 miRNAs, including the ten
spikes. In this passages, we paid attention to not exclude miRNAs present (or absent)
only in one of the two groups of patients considered (i.e., case and control).
Finally, the miRNA replicates within samples were summarized using the median.
A few missing values still present after the Ąltering step was imputed with k-nearest
neighborhood method. The distributions of the raw expression values are reported in
the Ąrst panel of Figure 4.2.
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4.3.2 Normalization
Global normalization methods developed for gene expression analysis are routinely
applied to circulating miRNA expression proĄling. However, the inappropriate assump-
tions and the reduced number of circulating miRNA proĄles raises some doubts about
the appropriateness of such methods.
In our study, in order to control the variability caused by experimental artifacts, we
added ten exogenous synthetic microRNAs (also called spikes) in a constant amount
across samples. These microRNAs are the best representation of variability due to
issues such as variation in starting materials, RNA extraction, or reaction eiciency.
In principle, after the normalization it is expected i) that spikes distributions were
stable at high expression levels across samples and with low variability and ii) that the
sample distributions be centered on the same mean.
To identify the best normalization technique, we performed a comparative eval-
uation using diferent normalization approaches: quantile [8], variance stabilization
normalization (vsn)[33], classic cyclic loess [91] and custom cyclic loess (CLWs) in
which spike controls are used as weights (see Section 3.3.1). Figure 4.2 shows the
normalized distributions. As you can see, none of the classic standardization models
(vsn, quantile or cyclic loess) is able to correct the technical variability of the experi-
ment, represented by the colored spike lines across samples. Conversely, the use of only
spikes as standardization factors - characterized by large values - leads to a bias of data
transformation around high expression levels. However, in this context, an appropriate
set of weights should contain both highs and low invariant expressed features.
For this reason, we included among the weights - in addition to the ten spikes - 20
invariant low expressed miRNAs, selected among those with expression values less than
3 (in log scales) and with the smallest diference in mean between cases and controls.
In general, the number of normalization factors (n) will depend on the total number of
proĄles remained after the Ąltering step, and the weight values (w) rely on the noise
contained in the raw data. Diferent combinations of parameters (n and w) have been
tried but with small diferences in performance (data not shown).
Summarizing, we assigned:
• high weights (w = 10) to ten synthetic, non-human, spike-in miRNAs to ensure
the correction of technical variability introduced in the pre-analytic steps;
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Fig. 4.2 Distribution of raw and normalized expression values with highlighted spike-in data
(colored lines). The type of normalization is reported on the right gray bar of each panel.
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Fig. 4.3 RLE plots of raw and normalized expression values with highlighted spike-in data
(colored lines). The type of normalization is reported on the right gray bar of each panel.
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• low weights (w = 1) to 20 context-speciĄc endogenous miRNAs to remove
diferences due to sampling selection and experimental quality;
• no weights for the remaining miRNAs, indeed the reduced number of features
measured tend to introduce high redundancy with a corresponding removal of
the interesting trends in the normalized data.
The application of this last strategy, hereafter called CLWsim, leads to the best com-
promise between a stable distribution of spikes expression values across samples and
centered array boxplots, as shown in the last panel of Figure 4.2.
Another basic plot to verify the goodness of normalization is the Relative Log
Expression (RLE) plot. The RLE plot shows the distribution of the ratio between the
expression of a miRNA and the median expression of this miRNA across all arrays of
the experiment. It is assumed that most miRNAs are not changed across the arrays,
so it is expected that these ratios are around 0 on a log scale. The boxplots presenting
the distributions should then be centered near 0 and have a similar spread. Another
behavior would be a sign of low quality.
The RLE plots obtained after each normalization is reported in Figure 4.3. As
expected classic loess, quantile, and vsn have more homogeneous RLEs, but a misguided
distribution of spikes. However, CLWsim normalization has the best compromise
between a stable distribution of spike expression and uniform distribution of RLE plots.
Then we decide to use CLWsim approach, as the best in our case.
4.3.3 Differential expressed miRNAs
The 638 microRNAs obtained after Ąltering and normalization steps were used for
diferential expression analysis, using eBayes method (Section 3.3.2).
A total of 97 microRNAs (15%) were identiĄed as diferential expression (DEM)
testing HGSOC serum versus healthy controls, 92 (95%) were up-regulated, while
Ąve (5%) down-regulated. It should be noted that, unlike gene expression analysis
where an equal number of up-regulated and down-regulated genes is expected, the
unbalanced Ąnding is in line with scientiĄc evidence on circulating miRNAs. In fact,
in studies aimed at detecting cancer-related circulating biomarkers, primarily a growth
in circulating miRNAs is expected, with respect to unafected individuals [73].
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Fig. 4.4 Cluster analysis using all differentially expressed miRNAs.
Similarity across samples was further investigated by unsupervised cluster analysis
(see Section 3.3.4) using DEM expression levels. The dendrogram depicted in Figure
4.4 shows a clear separation of three groups of patients, called C1, C2, and C3.
Except for seven healthy patients, cluster C2 and C3 are mainly composed of HGSOC
patients, while cluster C1 is largely composed of healthy controls. No signiĄcant
diferences have been observed regarding clinical characteristics of the C2 and C3
groups.
4.3.4 Tissue comparison
To investigate the origin of tissue of the selected DEMs, we examined miRNA expression
proĄles in those patients for whom matched serum and tissues were available (Section
3.2). To obtain consistent results, we employed the same models for both normalization
and diferential expression analysis in tissue data. In this case, however, given the rich
concentration of expression levels and the lack of measured endogenous spikes, in the
cyclic loess, the same weight was given to all microRNAs.
In particular, tissue raw microarray data comprised 2017 microRNAs. A Ąlter has
been applied to select those miRNAs with reliable expression values across arrays.
SpeciĄcally, we selected only miRNAs with at least 75% of good quality measures
(as gIsPosAndSignificant Agilent Ćag) across samples. After these Ąltering steps, we
remained with 363 miRNAs. Few missing values still present after the Ąltering step
were imputed with k-nearest neighborhood method. Classic cyclic loess and empirical
Bayes test have been applied to normalize raw proĄles and to identify diferentially
expressed miRNAs, respectively. Analysis revealed 265 DEMs (71%) - 123 up-regulated
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Fig. 4.5 The Venn diagram shows the partition of miRNAs found in serum, tissue, and
how many of these resulted differentially expressed in HGSOC samples compared to healthy
control (internal squared panel, DEMs). The bottom-left table shows a summary of these
partitions, while the right table shows name and trend (up and down adjusted) of the ten
DEMs common to both serum and tissue.
(46%) and 142 down-regulated (54%) - in HGSOC biopsies compared to 28 normal
tissues.
Only ten miRNAs resulted diferentially expressed in both matched tissue and serum
samples (Figure 4.5). Of these, eight miRNAs shared the same trend of regulation in
both tumors and sera, while two miRNAs (miR-1246 and miR-1972 ) displayed an
opposite pattern.
We further explored miR-1246 expression trend in HGSOC versus separately ovar-
ian and fallopian tube epithelia. Using our microarray data, we observed a signiĄcant
down-regulation of miR-1246 compared to ovarian epithelial (p < 0.0001), while the
comparison between miR-1246 levels in HGSOC tissues and normal fallopian tube
epithelia was not signiĄcant (p = 0.42). These results were conĄrmed by RT-qPCR,
using SNORD48 as reference for proper data normalization [6].
These discordances between tissue and serum miRNAs, both regarding the lack
of overlap between DEMs and the diferent proĄle trends, are in line with the results
shown in Jarry et al. [44]. In fact, detected alterations in circulating miRNAs reĆect
the systemic response to the presence of cancer and therefore can result not only from
the primer tumor but also from other types of cells, including immune cells [70].
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Rank miRNAs Case Control Adjust p-value log-FC
1 miR-483-3p 4.45 3.42 0.00001 1.03
5 miR-4290 4.06 3.10 0.00001 0.96
12 miR-595 5.03 3.54 0.0004 1.49
15 miR-2278 4.41 3.19 0.0005 1.22
18 miR-32-3p 5.19 3.37 0.0008 1.46
24 miR-3148 4.57 3.23 0.0008 1.34
50 miR-1246 7.18 6.24 0.0070 0.94
64 miR-574-5p 7.27 5.83 0.0154 1.44
73 miR-4281 11.37 10.50 0.0218 0.87
Table 4.1 Results of the microarray data analysis of the nine microRNAs emerged as best
candidates among DEMs for the validation phase.
4.4 Validation phase
miRNA analysis strongly depends on both the selected cohort and the technology
used in the discovery phase. To exclude the possibility that the performance of the
proposed biomarkers may be related to an unknown Şstudy biasŤ and the intrinsic
weaknesses of the proĄling method used, we decided to employ pre-operative sera from
an independent cohort, and a second technology to measure miRNAs concentration.
In the following, we present the choices we made in the selection of candidates
to be validated, starting from the set of DEM found in the discovery phase, and the
results obtained by RT-qPCR on this collection (Section 4.4.1). Also, a study on the
diagnostic potential of the best candidates is presented in Section 4.4.3.
4.4.1 Candidate selection and validation
Although the high-throughput nature of microarrays allows to analyze up to thousands
of miRNAs in one assay, typically has a low dynamic range and speciĄcity. Conversely,
the quantitative reverse transcription PCR (RT-qPCR) is a well-established method,
considered as the Şgold standardŤ for miRNA proĄling with high speciĄcity, dynamic
range, and sensitivity. For this reasons, it has been used during the validation phase.
However, due to the limits of PCR-based approaches, and the low abundance of
miRNA species in the sera of HGSOC patients, validation experiments were performed
only on a selection of DEM according to the following criteria: i) we selected only
miRNAs with at least 75% of good quality measures (not NA) across samples or within
patients or healthy controls, ii) highest log fold change, measured in patients compared
32 ANALYSIS and RESULTS
to healthy controls, iii) lower adjusted p-value.
Following these criteria, we identiĄed a panel of nine microRNAs (Table 4.1: miR-
1246, miR-574-5p, miR-483-3p, miR-4290, miR-595, miR-2278, miR-32-3p, miR- 4281
and miR-3148 ), two of which are DEM in matched tissue samples. Each of these has
been quantiĄed by qRT-PCR, and the diferential expression has been calculated on
the 2−Ct value, by t-test. Since there are no established endogenous miRNAs acting as
a reference for serum miRNAs, the raw Ct value has been normalized to the volume of
biological material. Finally, only miRNA expressions with Ct < 36 were considered
reliable. Table 4.2 summarizes the results obtained for both training and validation
set.
In the training set, miR-1246, miR-4290, miR-595, and miR-2278 (FC = 7.78,
FC = 1.97, FC = 2.08, FC = 7.01, respectively) are the most signiĄcantly up-
regulated miRNAs in the serum of patients compared to healthy controls. miR-574-5p
and miR-483-3p were not conĄrmed. RT-qPCR Ct values for miR-32-3p, miR-4281
and miR- 3148 resulted above the selected cut-of and therefore were discarded from
downstream validation.
In the validation set, accordant to previous results, the expression levels of miR-
1246, miR-595 and miR-2278 displayed a signiĄcant over-expression (FC = 3.11,
FC = 2.96, FC = 1.1, respectively) in the serum of HGSOC patients compared to
healthy controls. Conversely, miR-4290 showed an opposite trend. Collectively, these
results suggest that circulating miR-1246, miR-595 and miR-2278 in serum may serve
as candidate biomarkers for diagnosis of HGSOC (Figure 4.6).
4.4.2 A note on Ct normalization
To further support the robustness of our results, we have decided to standardize raw
Ct values through housekeeping.
However, housekeeping used for tissue miRNA analysis, such as RNU6, RNU48
or SNORD48 cannot be detected in circulation for their extensive RNAse-mediated
degradation [106]. The most popular alternative in the literature is undoubtedly the
miR-16, but it has recently recognized to be one of the most afected by hemolysis
and therefore can not be considered a reliable reference [80]. So, due to the lack of
a global consensus, independent studies have proposed other miRNAs as candidate
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Fig. 4.6 Boxplot diagrams showing the raw Ct values of miR-1246, miR-595, miR-2278
measured by RT-qPCR in sera of the training set (upper panel) and validation set (lower
panel). Control group refers to healthy controls and Case group to HGSOC patients.
Fig. 4.7 Boxplot diagrams of the RT-qPCR Ct values in sera of training (upper panel) and
validation (lower panel) sets patients, for miR-15b housekeeping. Control group refers to
healthy controls and Case group to HGSOC patients.
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Training Set Validation Set
Case
(Ct)
Control
(Ct)
p-value
(2−Ct)
Case
(Ct)
Control
(Ct)
p-value
(2−Ct)
miR-1246 25.83 23.41 < 0.00001 27.56 25.82 < 0.00001
miR-574-5p 28.16 28.32 0.6637 30.67 29.60 < 0.00001
miR-483-3p 32.44 32.72 0.9799 31.84 32.28 0.4145
miR-4290 33.40 32.62 0.0002 30.21 31.08 0.0344
miR-595 34.37 33.17 0.0002 34.13 32.85 < 0.0001
miR-2278 36.44 34.06 < 0.00001 33.58 33.39 0.0373
miR-32-3p 36.16 37.16 - 38.34 37.29 -
miR-4281 38.75 36.81 - 37.80 37.61 -
miR-3148 39.83 37.83 - 37.55 38.35 -
Table 4.2 Raw RT-qPCR data analysis results for each of the nine selected miRNAs. The miRNAs
that showed a significant over-expression in the serum of HGSOC patients compared to healthy
controls, both in training and validation sets, are reported highlighted.
Training Set Validation Set
Case
(∆Ct)
Control
(∆Ct)
p-value
(2−∆Ct)
Case
(∆Ct)
Control
(∆Ct)
p-value
(2−∆Ct)
miR-1246 0.957 0.868 < 0.00001 0.953 0.910 0.0041
miR-574-5p 1.022 1.038 0.1768 1.081 1.039 0.0068
miR-483-3p 1.200 1.214 0.3256 1.124 1.133 0.5754
miR-4290 1.221 1.191 0.0270 1.055 1.093 0.0132
miR-595 1.265 1.227 0.0098 1.197 1.155 0.0268
miR-2278 1.354 1.260 < 0.00001 1.167 1.176 0.4605
miR-32-3p 1.336 1.370 - 1.360 1.307 -
miR-4281 1.433 1.368 - 1.336 1.319 -
miR-3148 1.460 1.382 - 1.318 1.348 -
Table 4.3 Normalized RT-qPCR data analysis analysis results for each of the nine selected miRNAs.
miR-15b has been used has reference for the normalization. The miRNAs that showed a significant
over-expression in the serum of HGSOC patients compared to healthy controls, both in training and
validation sets, are reported highlighted.
housekeeping. Among these, the work of Bianchi et al. [5] suggests the miR-15b: it
resulted as the most invariant in our cohort of samples as well (Figure 4.7).
Using ∆Ct method, and miR-15b as a reference, we normalized the expression
levels of candidate miRNAs across all HGSOC samples and healthy controls. As shown
in Table 4.3, miR-1246 and miR-595 were also successfully validated by this further
normalization approach, either in training and validation cohort of samples. miR-4294
maintained its opposite trend. On the contrary, miR-2278 maintained its diferential
expression between HGSOC and controls in the training set (p < 0.0001), while not in
the validation set (p = 0.461).
4.4 Validation phase 35
Fig. 4.8 ROC curves showing the diagnostic performance of each single miRNA markers
in training and validation set, and the combination of the two of them. The curves were
estimated using raw RT-qPCR Ct values. Stars indicate the combination of sensitivity and
specificity with the highest AUC. In dashed dark gray, the model integrating the three
miRNAs. In dashed light gray the random classification.
36 ANALYSIS and RESULTS
(a) miR-1246 ROC performance
Threshold Specificity Sensitivity Accuracy
Training Set 24.95 0.71 0.93 0.86
Validation Set 26.77 1 0.77 0.82
Combined 0.41 0.77 0.87 0.84
(b) miR-595 ROC performance
Threshold Specificity Sensitivity Accuracy
Training Set 32.47 0.86 0.44 0.57
Validation Set 32.65 1 0.48 0.58
Combined -0.29 0.84 0.47 0.57
(c) miR-2278 ROC performance
Threshold Specificity Sensitivity Accuracy
Training Set 35.38 0.69 0.91 0.84
Validation Set 33.13 1 0.31 0.44
Combined 0.26 0.66 0.81 0.77
Table 4.4 Diagnostic performance of selected miRNA biomarkers in the training set, in the
validation set and in the combination of both sets. Specificity, sensitivity and accuracy have
been calculated at the selected threshold as described in Section 3.3.3.
4.4.3 Diagnostic potential
As we can observe (Figure 4.8), all three miRNAs perform best than the random
classiĄcation of patients (gray dotted line). In particular, for miR-1246 (Table 4.4a)
the sensitivity is 87%, the speciĄcity is 77%, and the accuracy is 84%, with an AUC
(Area Under the Curve) of 0.89. For miR-595 (Table 4.4b), the sensitivity is 47%,
the speciĄcity is 84%, and the accuracy is 57%, with an AUC of 0.69. For miR-2278
(Table 4.4c), the sensitivity was 81%, the speciĄcity is 66%, and the accuracy is 77%,
with an AUC of 0.76.
Then, we tested the diagnostic value of the integration of the three biomarkers,
using multivariate logistic regression. We found that miR-1246 remains the strongest
biomarker (p = 2.3e−09), while miR-595 (p = 0.41) and miR-2278 (p = 0.14) resulted
to be not signiĄcant. Moreover, the combination of the three biomarkers resulted in a
moderate increase of AUC only in the validation set.
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Fig. 4.9 Boxplot of the absolute quantification of miR-1246 by ddPCR in HGSOC patients
compared to controls, for both training and validation sets. Results are presented as copies
per microliter of the amplification reaction mixture.
These results indicated that miR-1246, which showed the greatest ability in diferen-
tiating HGSOC patients from controls, could act as a suitable biomarker for detecting
HGSOC patients.
4.4.4 Additional validation
As miR-1246 appeared the most promising diagnostic serum biomarker, we decided to
validate its expression levels with an additional and more sensitive technique, EvaGreen-
based ddPCR technology. The quantiĄcation by ddPCR expressed as copies/µl (Figure
4.9), conĄrmed the diagnostic potential of miR-1246 (p < 0.0001) in discriminating
HGSOC patients and healthy controls.

Chapter 5
CONCLUSIONS
Considering the lack of ovarian cancer screening tests that can signiĄcantly reduce
patient mortality, developing new strategies for early diagnoses, such as identifying new
biomarkers, is one of the possible strategies to be pursued. Serum tumor biomarkers
are currently considered one of the best tools to improve early diagnosis, help to predict
prognosis and possibly therapeutic response. They are particularly relevant for a
neoplastic disease such as ovarian cancer, which is often asymptomatic at its start and
tissue samples are not always accessible during clinical follow-up.
In recent years, circulating miRNAs have been discovered and found highly stable in
a variety of body Ćuids that can be minimally invasive. Although the expression levels
of circulating miRNAs reĆect the cumulative efects of diferent negative pathways,
which have not yet been fully elucidated, the levels and composition of miRNAs in
blood, serum or plasma have been found to reĆect the presence of several malignant
diseases. Many technical challenges in the analysis of circulating miRNAs complicated
the comparison of independent data sets and delayed their entry into clinical environ-
ments.
In the presented study, published in Cancer Letters journal [99], we used microarray
technology to achieve efective selection of the most promising miRNAs among the
thousands of possible candidates coming from miRNome (miRBAse version 19). In
addition, we have developed a new bioinformatic approach to identify speciĄc circulating
miRNAs that characterize HGSOC patients.
The miRNA proĄles of the training set initially allowed us to identify 97 miRNAs
with diferent levels of expression (DEM) between HGSOC patients and healthy controls.
In line with previous studies, we found a modest overlap between miRNA expression
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pattern in serum and tissue [44, 111], suggesting that circulating miRNAs could derive
from a contribute of inĆammation-related and tumor-speciĄc miRNAs, selectively and
actively secreted through microvesicles and exosomes as a novel mechanism of genetic
exchange between cells.
Among DEMs, nine of these were further validated in a completely independent
data set, of which miR-595 and miR-1246 were conĄrmed in both. The ROC curve
conĄrmed miR-1246 as the most promising diagnostic biomarker, as it was able to
accurately classify cancer patients concerning healthy controls, both in training and
validation cohorts.
Currently, serum CA-125 is the most frequently used biomarker for EOC detection,
showing the best performance in advanced-stage HGSOC, while exhibiting both a
low speciĄcity and sensitivity to detect early-stage disease. Consequently, prospec-
tive studies on a larger cohort of serum samples are needed either to test miR-1246
potential clinical utility in late-stage HGSOC or to assess its value in early-stage
diagnosis. Although a detailed biological analysis of miR-1246 is far from the scope of
this study, there are some data previously reported in the literature that is warranted
to be discussed in detail. Its expression has been largely reported as upregulated in
various cancer tissues [36, 49], and as circulating marker, it has been proposed for the
detection of several carcinomas [75, 89]. Moreover, miR-1246 has been associated with
stemness in non-small cell lung cancer [49] and pancreatic carcinoma [36]. According
to our knowledge, miR-1246 has not previously been associated with ovarian cancer,
either at tissue level or serum level. Indeed, despite the abundance of published
articles on miRNA circulating in the diagnosis of ovarian cancer, there is a high level
of inconsistency in the studies. Pre-analytical and analytical challenges in circulating
miRNA experiments, data analysis and normalization, statistical power, and validation
of results, are the principal causes of this poor overlap in the outcomes.
Within this complex scenario, we believe that our study displays several improved
features compared to previous studies, including:
(i) the focus on HGSOC, the most frequent and aggressive ovarian carcinoma subtype;
(ii) optimized protocols including collection, handling, hemolysis monitoring, storage
and miRNAs extraction of serum samples;
(iii) the inclusion of two cohorts of HGSOC patients and controls, gathered from
independent serum collections;
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(iv) the use of an innovative and efective statistical approach of microarray data
normalization, combining synthetic spike-in RNA oligos and the most invariant
endogenous miRNAs;
(v) the use of two RT-qPCR techniques for miRNA validation and, in particular,
of Exiqon primer sets with LNA technology, which maximizes sensitivity and
speciĄcity in detecting miRNA amplicons.
This rigorous approach makes us conĄdent in our results, reporting miR-1246 as a novel
diagnostic biomarker in HGSOC. Moreover, we believe that the presented experimental
design can be used as a guideline for other studies concerning circulating miRNAs.
In fact, we are currently adopting the same strategy in a second study of saliva
samples from a cohort of Head and Neck Squamous Cell Carcinoma (HNSCC) patients.
In particular, also in saliva samples, the proposed customized normalization approach
showed the ability to correct confounder variables. Further evaluations on the list of
diferentially expressed miRNAs, should be made to conĄrm the validity of the results
and to identify possible biomarkers for HNSCC.

Part II
Primary genes detection in
perturbed biological
pathways

Chapter 6
INTRODUCTION
6.1 Omics data and system biology
In the last two decades, biology has become a Şbig-dataŤ science. With the Ąrst
bacterial genome sequenced and the consequent optimism generated [31] by the Human
Genome Project [103, 52], we have seen the begginning of an era characterized by the
extensive collection of biological information and the consequent birth of the so-called
ŞomicsŤ sciences.
Modern high-throughput technologies (HTs) - such as genomics, proteomics, and
transcriptomics - are providing tons of data that grow in a multidimensional way over
time and lead to more and more detailed information. In fact, HTs allow researchers
to perform complete measures of the molecular status of biological samples and furnish
lots of information on gene association with particular phenotypes.
Regardless of the technology used, high-throughput data analysis typically yields
long lists of genes or proteins whose expression change in diferent experimental
conditions (DEGs) [59]. There are several univariate statistical methods to establish
the diferential expression of these molecules, such as t-test, non-parametric tests, and
Bayesian models [28].
These lists are handy for identifying genes that may have a role in a given pheno-
type. However, for many investigators, they donŠt often provide mechanistic insights
into the biological condition contributing to a limited understanding of complex diseases.
Indeed, the adaptable nature of living systems constitutes a signiĄcant challenge to
derive accurate and predictive models from genomic data. Because cellular processes
are governed by networks of molecular interactions, critical alterations to these systems
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may arise at diferent points, yet result in similar phenotypes. Typical gene-level
analyses of HT data, such as tests of diferential expression, are unable to capture
these efects [10].
There is growing consensus that the genetic risk for a complex disease is mainly
due to multiple genes with small but coordinated interactions that act in a modular
fashion, rather than by the diferential expression of a single gene [97]. As a result, the
advent of HTs has increased the interest in the systems-level analysis of genomic data.
6.2 Gene Set Enrichment Analysis
One of the most promising and widely used computational approaches analyzing data
coming from HTs is the Gene Set Enrichment Analysis (GSEA). To reduce the com-
plexity of the analysis, the idea is to move from the gene-to-gene view, towards the
analysis of a group of functionally related genes. Researchers have developed a large
number of knowledge bases to facilitate this task. These knowledge bases describe
biological processes, components, or structures in which individual genes are involved,
and how and where gene products interact with each other. An example of this idea is
to identify groups of genes that work in the same pathway.
The pathway-based analysis (PA) - also known as functional enrichment analysis
- is desirable for two reasons. First, grouping thousands of genes, proteins and/or
other biological molecules reduces complexity to a hundred pathways per experiment.
Secondly, identifying pathways that difer between two conditions may increase the
explanatory power of the simple list of genes or proteins. This procedure has shown a
better understanding of the molecular mechanisms that cause complex diseases [106].
The development of PA techniques has been made possible by the growth of
databases that describe the functional networks of interactions. Among these are
KEGG [47], Reactome [29], BioCarta [71], NCI Pathway Interaction Database (NCI-
PID) [86] and WikiPathways [51]. Also, to address the challenge of querying these
databases using a common framework, Markup languages such as KGML and BioPAX
[21] have been developed to describe pathways using a consistent format. Finally,
several tools have been proposed for the conversion of a biological pathway into suitable
graphical and mathematical structure [84, 104, 109].
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Over the past decade, a considerable number of methods have been developed to
integrate this information, both in the univariate and multivariate case. According to
the statistical test adopted and the hypotheses tested, PA methods can be divided into
two broad categories. The Ąrst group comprises models designed to identify pathways
in which signiĄcant genes are overrepresented. Some examples are the GSEA [93]
and the Ingenuity Pathway Analysis. The second category of methods is based on
global and multivariate approaches that summarize the variation of the genes across
the pathway and test for pathway level diferences, without relying on single gene
association statistics. Goeman and Buhlmann [34] term these approaches competitive
and self-contained, respectively.
Both approaches have their limitations. On the one hand, competitive methods
assume the independence among genes and use a stringent cut-of for the selection
of DEGs, leading to a reduction in statistical power. On the other hand, global and
multivariate approaches relax the assumption of independence of genes from the same
pathway - identifying moderate but coordinated diferences - but tend to have high
power, leading too many signiĄcant tests. For the latter, the number of replicas in
experiments is often too low for multivariate models.
6.3 Topological Pathway Analysis
Despite these advances, most of PA methods manage pathways as a simple list of
genes, ignoring the fact that they are structured in a network with explicit interactions.
Moreover, the contribution of the network topology to biological functions has long
been appreciated and proven [92]. So, even if our understanding of biological functions
is continually improving - and pathways are regularly updated by adding, removing
or re-mapping links in the diagrams - as long as they involve the same set of genes,
they will produce identical results. In recent years, eforts have been made to consider
topological information within self-contained methods, thus seeing the emergence of
the third generation of models, called Topological Pathway Analysis (TPA).
The seminal paper of Draghici et al. [25] proposes one of the Ąrst approaches
(Impact Analysis, SPIA [94]). They attempt to capture and combine two diferent
aspects of data: i) the overrepresentation of DEGs in a given pathway through fold-
change and ii) the abnormal perturbation of the pathway, measured by propagating
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expression changes across its topology. Since then, this approach has become very
popular, resulting in the publication of several pathway topology based algorithms [48].
Other attempts to incorporate topological information into pathway analysis make
use of graph theory methods. Isci et al. [40] propose a Bayesian pathway analysis
that models each biological pathway as a Bayesian network; Vaske et al. [102] use a
probabilistic graphical model framework for learning the underlying causal networks
compliant; Jacob et al. [41] develop a graph-structured two-sample test for means.
Finally, Massa et al. [62] introduce a Gaussian graphical model approach that exam-
ines both diferences in means and in covariance matrices between two experimental
conditions.
Although itŠs hard grouping these methods into macro categories because of the
heterogeneity of the proposals, they can be categorized by diferent criteria, including
the type of input required, the mathematical model used, the chosen implementation,
and the provided output [67]. From the output, the result is typically a list of ordered
pathways.
In most of the methods described above, individual values that represent gene
expression are combined - following the pathway-deĄned internal structure - into a
single global score that results in activation/deactivation. Then, the pathways are used
as whole functional units in the interpretation of phenotype association experiments.
However, stating that a pathway is activated (or deactivated) is not very informative
by itself. Indeed, partial activation (or deactivation) within the same pathway can
have very diferent and sometimes opposite biological implications [87].
For this reason, some methods propose a subsequent reĄnement of the analysis
by identifying sub-networks consistent with the condition under study [42, 90, 63].
This ability is essential when the pathway contains hundreds of genes. In fact, the
signiĄcance of a large pathway could be misleading, hiding signiĄcant parts that are
mostly involved in the biological process under exam.
Some of the most recently proposed approaches seek to model signiĄcant sub-
pathways as signal paths or perturbation chains that can guide systematic diferences.
They can result in a more detailed and realistic description of functional consequences
of gene up and down regulations within the context of each pathway.
Li et al. [57], attempt to identify biologically signiĄcant pathways by using a
minimum spanning tree and an extension of the SPIA mentioned above. In this
case, the signal is represented by diferentially expressed and related genes through
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linear structures. Instead, Vrahatis et al. [105] use the union of pathways to extract
diferentially expressed gene modules characterized by Ąve speciĄc topological structures
(components, streams, cascades, and neighborhoods).
From an entirely diferent angle, Sebastian-Leon et al. [87] adopt a probabilistic
model in which gene expression measurements are used to calculate the probability of
activation of stimulus-response circuits within pathways. Finally, Martini et al. [61],
use chains of modules (cliques), obtained through a structure - called junction tree - to
identify the signal path most associated with the phenotype.
6.4 Motivation Problem
Although authors tend to interpret genes that are part of perturbed sub-graphs as
disease-causing biomarkers and likely targets for therapy, this may not be true. Indeed,
all above mentioned models, using marginal approaches, are unable to distinguish be-
tween the genes that are the real sources of perturbation (for example due to mutations,
number variations, epigenetic changes, etc.) and those that merely respond to signal
dysregulation, due to the so-called network propagation.
Let us take the example of intervention studies, such as knock-out and knock-in.
Here, the expression of a single gene is altered. Marginal approaches will identify all
pathways or sub-pathways that include the gene - as a consequence of the intervention -
without giving any information about the direct target of the intervention. For example,
although Ansari and colleagues [3] propose a formulation that explicitly distinguishes
between Şprimary disregulationŤ and Şsecondary disregulationŤ, are incapable of iden-
tifying the knock-down gene. They merely use this information to improve pathway
perturbation scores. Also, although in the intervention studies the gene that generates
the phenotype is known, it may be not annotated in any pathway, or its function may
be undiscovered. In this case, the identiĄcation of primary regulators can help the
experimenter to identify the direct targets of the perturbed gene. Another compelling
application - which goes in the direction of precision medicine - is case-control studies:
the identiĄed set of genes will be responsible for the diferences that cause the observed
perturbation, and then may be the upstream regulators.
To Ąll this gap, we propose to pursue the identiĄcation of the set of variables driving
the diference in diferent experimental condition (i.e., the primary genes) within a
graphical model context [23]. We present a new way to address this question, which
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uses the idea of simultaneously looking at the diferences between two multivariate
normal distributions (i.e., two phenotypes) in all marginal and conditional distributions
implicated by Markov properties, associated with a non-directed and decomposable
graph representing the pathway under exam. This model can be thought as the natural
extension of the method proposed by Massa et al. [62] for identifying primary genes.
We had also implemented the algorithm and made it available as an R package with
additional graphical devices, to guide the user in the exploration of research Ąndings.
In the Ąrst chapter (Chapter 7), we present all the fundamental notions regarding
the proposed method. A deepening discussion about the used strategies to overcome
the limitations inherited by high-dimensionally and the multiple tests issue can be
found in Section 7.3. The aspects related to the implementation of the algorithm are
listed in Chapter 8. Finally, the evaluation of the model performances on both in-silico
and real biological data are presented in Chapter 9.
Chapter 7
METHODS AND RATIONALE
7.1 Theoretical Background
When a set of genes functionally related to gene set categories (i.e., pathways) are
Ćagged to be associated with a certain phenotype, the fundamental biological question
is to identify - among the genes involved - those that are potentially responsible for
diferential behavior to determine possible biomarkers or therapeutic targets.
An approach based on graphical models, allowing to search for both diferential
expression and co-expression behavior, was proposed by Massa et al. [62]. After
converting the pathway to an appropriate graph where the nodes and edges represent
genes and biochemical interactions respectively, the authors assume to model the data
through two Gaussian graphical models with the same undirected graph.
Within the context of graphic models, data is considered as coming from Gaussian
multivariate distributions with a structured concentration matrix (inverse of the
covariance matrix), which reĆects dependencies between the variables derived from the
pathway topology conversion. Formally:
(X(1)1 , ..., X
(1)
p ) = ¶Y ∼ Np(µ
(1),Σ(1)), (Σ(1))−1 ∈ S+(G)♢
(X(2)1 , ..., X
(2)
p ) = ¶Y ∼ Np(µ
(2),Σ(2)), (Σ(2))−1 ∈ S+(G)♢
where p is the number of variables (number of genes) and S+(G) is the set of symmet-
ric positive deĄnite matrices with null elements corresponding to the missing edges of G.
The authors can formulate a topological approach to gene set analysis that trans-
forms the encoded dependency structure contained in pathways into undirected graphs
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and models them as Gaussian graphical models. In this context, the assessment of
whether the pathway expression changes in diferent experimental conditions naturally
Ąts within the hypothesis tests on the mean and variance/covariance parameters for
which the inference procedures are well characterized [54]. Which is:
H0 : Σ(1) = Σ(2) vs H1 : Σ(1) ̸= Σ(2)
H0 : µ(1) = µ(2) vs H1 : µ(1) ̸= µ(2)
The Ąrst one tests if the strength of the connections among genes is altered in diferent
experimental conditions; the second test is more traditionally designed for testing
diferential expression, nevertheless in a multivariate setting.
Once the hypothesis of equal distribution is rejected, the pathway is deĄned as
perturbed (activated or deactivated). The modular nature of Gaussian graphical models
allows identifying the portion of the graph that is mostly associated with the phenotype
under study. So, authors partition the graph into smaller units - the so-called maximal
cliques - and tests are performed for each of them. In fact, when the underlying graph
is decomposable, cliques induce saturated models that can be tested separately and
compared marginally.
The main criticism of the method proposed by Massa et al.[62], concerns the
dependence of the tests associated with the cliques being these non-disjoint and
overlapping sets of variables. It is common for biological networks that some nodes
have a degree of connectivity higher than others (i.e., hub genes): when the pathway
is translated into a graphical structure, these nodes tend to be in almost all cliques,
dramatically amplifying the dependence of the tests.
This issue can be addressed by decomposing the global test in moving from marginal-
based to conditional-based approach, to obtain independent hypothesis. Although the
conceptual framework needed to achieve this formulation has already been introduced
in the seminal work of Dawid and Lauritzen [19] - under the name of Hyper Markov
Laws - the implementation of this theory has never been applied in the biological
context. The ultimate goal is to provide the researchers with a tool that allows to zoom
on the potential sources of diferential behaviors, identify the causes, and translate
results into biological hypotheses that can be experimentally validated.
Determining the set of variables that are the actual source of the diferences between
two phenotypes - what we will call from now on source set - is the purpose of the
proposed method.
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Fig. 7.1 Decomposable graph G consisting of six nodes (♣V ♣) and three cliques (k).
7.2 The source set
In this chapter, we will introduce the idea of source set - the set of variables that are
the true source of the diferences observed between two conditions - through a toy
example (Section 7.2.1). This example will serve to fully understand the diference
between using a marginal approach rather than conditional, and it will be utilized
throughout the chapter to introduce diferent concepts. We will formalize this notion in
(Section 7.2.2). Finally, we will show how the modularity of the graphical models can
be used to decompose the global hypothesis of equality of two distributions (Section
7.2.3) into a set of local independent hypothesis that can be exploited to estimate the
source set (Section 7.2.4). Some typical issues of inference on high-throughput data,
such as small sample size and multiple testing, are addressed in (Section 7.3).
All the fundamental notions regarding the graphical models, relevant to the un-
derstanding of the following paragraphs, can be found in Appendix A. For a detailed
view, see Lauritzen [54]. All the theorems, the demonstrations and further details
regarding the source set are contained in the work of Djordjilović et al. [23]. Instead,
for information on pathway topology conversion into an undirected decomposable
graph, refer to Massa et al. [62]. For a more detailed view of Sales et al. [84].
7.2.1 Marginal and conditional distribution
Let us consider the graph G = (V,E), represented in (Figure 7.1), and a vector of causal
variables (X1, ..., X6) with the associated normal multivariate distribution N6(µ,Σ),
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(a) Mean (b) Correlation
(c) Partial correlation
Fig. 7.2 Mean (a), correlation (b) and partial correlation (c) parameters in control and
intervention conditions. Parameters directly affected by the intervention are highlighted
(red). Line y = x added for reference (gray dashed line).
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where µ ∈ R6 is arbitrary, and Σ−1 ∈ S+(G) obeys to the conditional independence
encoded in G. Two variables are said to be conditionally independent when their
partial correlation - that is, the corresponding element of Σ−1 - is zero, and G is an
undirected decomposable graph. We can think of X1, . . . , X6 as the expression levels
of six genes, and G as the dependency structure among these in a given pathway.
We assume that variables X3 and X4 are the true sources of perturbation (i.e., due
to mutations, epigenetic changes, etc.), while the remaining variables - X1, X2, X5
X6 - merely respond to the perturbation of the signal. More speciĄcally, compared to
the control condition, the mean of X3 decreases by 70%, and as a result, the partial
correlation between X3 and X4 reduces in turn. In other words, the intervention inĆu-
ences the mechanism underlying the joint distribution by acting on the two variables,
but it leaves unaltered the conditional distribution of the remaining variables (Figure
7.2c). It afects all the marginal distributions considered, both for the mean and for
the variance matrix, as illustrated in (Figure 7.2b) and (Figure 7.2a).
We generate a random sample of size 100 for each condition (i.e., before and after
intervention on variable X3 and X4). Following the strategy presented in Section 7.1,
we decompose the graph into its maximal cliques and perform the marginal test of
equality of distributions on each of these. Note that in this case we are considering
the null hypothesis H0 : Σ(1) = Σ(2) and µ(1) = µ(2). As expected, all cliques are highly
signiĄcant (Table 7.1), in fact, they all contain variables on which we intervened. Since
all marginal distributions between the two conditions are diferent, we would conclude
that the condition under study has an impact on all variables. Although correct, this
view fails in identifying the special role of the variables X3 and X4, which are the
primary genes of the perturbation. If we adopt the terminology proposed by Ansari
et al. [3], we are not able to distinguish between the Şprimary dysregulationŤ of a
given set of genes itself and the efect of signal propagation, that is the Şsecondary
dysregulationŤ. Moreover, the authors assume that it is the leading cause of the large
number of false positive which the TPA methods proposed so far presently facing.
7.2.2 Definition
Resuming the idea shown in the previous paragraph, we can give a more formal
deĄnition of the set of our primary genes. Suppose we have p variables, and two normal
random vectors X(1) and X(2), which represent the distributions of the variables in the
two experimental conditions.
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Element A λ(A) Gdl p-value
C1 ¶X1, X2, X3, X4♢ 231.95 14 1.5× 10−41
C2 ¶X3, X4, X5♢ 225.58 9 1.4× 10−43
C3 ¶X3, X5, X6♢ 48.93 9 1.7× 10−7
S2 ¶X3, X4♢ 224.71 5 1.4× 10−46
S3 ¶X3, X5♢ 43.74 5 2.6× 10−8
Table 7.1 Test of equality distribution of cliques and separators induced by G. Significant
p-values are highlighted.
Definition 1. We call the set D the minimal source set, if:
1. the distribution of X
(1)
D differs from that of X
(2)
D ;
2. the conditional distributions X
(1)
D¯
♣X(1)D and X
(2)
D¯
♣X(2)D coincide
where D is a subset of the p variables, and D¯ its complementary.
In our toy example, the source set D is equal to the set (X3, X4). In fact, the
distribution of the set of variables D¯ = ¶X1, X2, X5, X6♢ conditioned to the source set
will be the same in the two conditions, for construction.
A naive strategy to identify the set D from data would require testing all possible
subsets of V, but the number of potential source sets grows with the power of p, making
the search space too large for many practical applications. This deĄnition is general
and does not refer to the graph structure.
However, when comparing two normal distributions, we can take advantage of the
decomposable graphs and the modularity implicated by hyper Markov properties to
obtain a linear solution.
7.2.3 Decomposition of the global hypothesis
Let G = (V,E) be a decomposable undirected graph on p vertices. Let C1, ..., Ck be a
sequence of its cliques satisfying the running intersection property, and let S2, ..., Sk be
an associated sequence of separators (for deĄnition, see Appendix 7.4). LetŠs remember
that a clique is a complete maximal subgraph, that is not a subset of any other complete
subgraph, and a subgraph is said to be complete if all its vertices are connected to G.
Let X(1)1 , ..., X
(1)
n1
and X(2)1 , ..., X
(2)
n2
be two random samples from two multivariate
normal distributions X(1) ∼ Np(µ(1),Σ(1)) and X(2) ∼ Np(µ(2),Σ(2)) and consider the
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hypothesis of equality distributions
H0 : Σ(1) = Σ(2) and µ(1) = µ(2) (7.1)
and the hypothesis of equality distributions for the satured marginal model induced by
the subset of variable A ⊆ V
HA : Σ
(1)
A = Σ
(2)
A and µ
(1)
A = µ
(2)
A (7.2)
Theorem 1. Let λ(V ) denote the log likelihood criterion for testing (7.1) and λ(A) the
log likelihood criterion for testing (7.2). Thanks to the Hyper markov laws associated
to the graph G, the global hypothesis of equality of X(1) and X(2) decomposes into a set
of independent local tests, as follow:
λ(V ) = λ(C1) +
k∑
i=2
[λ(Ci)− λ(Si)] (7.3)
Moreover, under the null hypothesis, the k terms on the right hand side are asymptoti-
cally independent chi-squared distributions.
At this point, it is necessary to explain the interpretation of the k components of the
decomposition (7.3) to clarify how this formulation plays a key role in estimating the
source set. The Ąrst term λ(C1) corresponds to the log likelihood ratio (LLR) criterion
for testing the equality of the marginal distributions of the C1 clique, i.e. XC1 ; while
the (k − 1) terms on the right, correspond to the LLR for testing the equality of the
conditional distribution of the variable belonging to Ci, given the variable belonging to
the associated separators Si, i.e. XCi\Si♣XSi . Note that, thanks to this decomposition,
we do not explicitly estimate any conditioned dependence, but we only need to perform
marginal tests in small models induced by cliques and separators, associated to the
graph G.
Looking at the toy example, graph G consists of three cliques and two separators.
A proper sequence is (C1, C2, C3) and the associated sequence of separators is (S2, S3).
Following (7.3), the global statistics can be decomposed as:
λC1(V ) = λ(C1) + [λ(C2)− λ(S2)] + [λ(C3)− λ(S3)]
where the Ąrst component tests the equality of the marginal distribution ofX1, X2, X3, X4,
the second tests the equality of the conditional distribution of X5 given (X3, X4), and
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the third of X6 given (X3, X5). We are dealing with diferent partitions of the set of
vertices and each variable enters a single time in the hypothesis system. It should be
noticed that such an ordering naturally leads to avoid the dependence among tests.
However, despite the fact that graph G determines the set of cliques and separators,
the orderings that satisfy the running intersection property are not unique.
Given the uniqueness of the separators, it is easily demonstrable that there is
precisely one decomposition for each choice of the root clique of the sequence (i.e., the
clique that corresponds to the marginal test of the decomposition) leading to a total of
k decompositions, where k is the number of cliques. Other permissible, and equally
valid, decompositions, are:
λC2(V ) = λ(C2) + [λ(C1)− λ(S2)] + [λ(C3)− λ(S3)]
λC3(V ) = λ(C3) + [λ(C2)− λ(S3)] + [λ(C1)− λ(S2)]
Since each of these orderings corresponds to a diferent factorization of the same
distribution, this multiplicity can be exploited to obtain a set of alternative views on
the joint distribution under study and to estimate the source set.
7.2.4 Estimate
We can estimate the source set by inspecting the decompositions obtained by exploiting
the structure of the graph and the modularity implicated by Hyper markov laws as
follows.
To identify the i-th decomposition, obtained when Ci is set as the root clique, we
let Ci,1, ..., Ci,k denote a sequence of cliques satisfying the running intersection property.
Let Si,2, ..., Si,k be an associated sequence of separators, and set Si,1 = ∅, i = 1, ..., k.
The (7.3) can be reformulated as:
λCi(V ) =
k∑
j=1
[λ(Ci,j)− λ(Si,j)] (7.4)
Let assume that we collect n1 and n2 observations from X(1) and X(2), respectively.
For each i-th ordering and for each components λ(Ci,j)− λ(Si,j) deĄned in (7.4), we
test the Hi,j hypothesis of the equality of the two distributions. Finally, we save the
result of the (k × k) tests in a vector ϕi = (ϕi,1, ..., ϕi,k) ∈ ¶0, 1♢k , where ϕi,j = 1 if
the null hypothesis is rejected, and ϕi,j = 0 otherwise. Note that, since Si,1 is always
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Decomposition Component λ(Ci)− λ(Si) Gdl p-value DˆG,i
λC1(V )
C1 231.94 14 1.5× 10−41
{ C1 }C2♣S2 0.87 4 0.93
C3♣S3 5.19 4 0.27
λC2(V )
C2 225.58 9 1.4× 10−43
{ C2 }C1♣S2 7.23 9 0.61
C3♣S3 5.19 4 0.27
λC3(V )
C3 48.93 9 1.7× 10−7
{ C3 ∪ C2 }C2♣S3 181.84 4 3.0× 10−38
C1♣S2 7.23 9 0.61
Table 7.2 Marginal and conditional tests for the k decompositions of G. Significant p-values
are highlighted.
the empty set, the Ąrst component is the LLR test on the marginal distribution of the
root-clique of the i-th sequence.
Definition 2. The random set DˆG defined as:
DˆG =
k⋂
i=1
⋃
j:ϕi,j=1
Ci,j (7.5)
is an estimator of the minimal source set D.
In other words, the estimated source set consists of the set of shared variables,
associated with marginal and/or conditional signiĄcant tests for all the orderings
induced by the decomposition allowed by the graphical structure G.
It should be stressed that DG - the graphical source set - could be not equal to the
minimum group of variables that explain the diferences between the two experimental
conditions. The level of detail depends on the size of the cliques and the separators
of the graph G. The graphical source set DG and the minimum source set D will
be equal in certain situations, such as every time the set of the primary genes is a
separator within the graph. It can be thought of as the price to pay for not considering
all possible subsets of ¶X1, .., Xp♢. For more details, see Djordjilović et al. [23].
7.2.5 A guided illustration
To summarize the proposed procedure, we consider the toy example of (Section 7.2.1).
We generated a random sample of 100 for each condition.
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Fig. 7.3 The k possible decompositions of G for different choices of the root clique. Subsets
corresponding to DˆG,i, i = 1, 2, 3 are highlihted. The sequence of cliques Ci,1, ..., Ci,k and
the associated sequence of separators Si,1, ..., Si,k for each decomposition are reported on the
bottom.
All possible decompositions for the graph G are three (Table 7.2), i.e., the number
of cliques. Each of these decompositions consists of a marginal test (i.e., the root-clique)
and two conditional tests. Since the conditional test statistic is just the diference
between marginal tests, we can limit ourselves to performing tests on cliques and
separators. Each marginal test statistic has a chi-square distribution with p× (p+3)/2
degree of freedom (gdl), where p is the number of variables of the considered set (Table
7.1), i.e., the cardinality.
For each decomposition, the three obtained test statistics are asymptotically inde-
pendent, and we can calculate the asymptotic p-value from a chi-square distribution.
The degrees of freedom for the conditioned tests will be equal to the diference between
the gdl of the test on the clique and the separator. The results are shown in (Table
7.2). For example, if we look at the decomposition λC1(V ), the Ąrst test is signiĄcant
while the other two do not, although C2 and C3 are marginally signiĄcant (Table 7.1).
It means that the diference in marginal distributions is fully explained by the changes
in the marginal distribution of the Ąrst clique. These conclusions can be extended to
the remaining two decompositions.
We combine the results of the three decompositions according to (7.5) and obtain
ϕ1 = ¶1, 0, 0♢, ϕ2 = ¶1, 0, 0♢ and ϕ3 = ¶1, 1, 0♢ , which leads to DˆG = ¶X3, X4♢ (Figure
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7.3). Thus we have identiĄed the true source set D, which, being a separator, coincides
with the minimum source set.
7.3 Practical Issue
When applied to data coming from HT technologies, our method sufers from all
limitations inherited by high-dimensionality - the small number of samples compared
with the huge number of genes - and multiple tests issue - the system-level analysis -
making the proposed method applicable to a limited number of real applications.
In the next sections, we discuss these two issues and describe the methods proposed
to solve them properly.
7.3.1 Small sample size
The basic block of our method is the likelihood ratio statistic. A necessary condition
for the existence of the maximum-likelihood estimate is that the number of samples for
the smallest group n = min(n1, n2) is greater than the cardinality of the largest clique
p = max(♣C1♣, ..., ♣Cp♣). In fact, when we estimate the sample covariance matrices Σ,
Σ(1) and Σ(2) these must be positive deĄnite.
Moreover, even when the number is suicient and the estimate of maximum likeli-
hood exists, given the asymptotic nature of the log likelihood test the distribution for
Ąnite sample may be far from its asymptotic distribution. In fact, even for moderate
number (i.e., n ≈ p), the sample covariance matrix can no longer be considered a good
approximation of the true covariance matrix.
In these cases, we suggest using a ridge estimator (i.e., the addition of a penalty
to the log-likelihood) by summing a small quantity to the diagonals of these matrices.
Then, we calculate the observed variance distributions in the two conditions and the
pooled sample, compute the Ąfth percentile of each of these distributions, and use the
minimum as the regularized quantity [39]. This approach allows us both to stabilize
the estimates of the covariance matrices and to make comparable the LLR criterion
among distributions.
However, if a regularized estimator for the covariance matrices is employed, permu-
tation methods have to be applied to derive an approximation of the null distribution
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of the test statistics. It must be emphasized that the permutational approach can be
used because of the exchangeability property of the observations under the equality of
the two distributions. This is not the case when means or variance equality hypotheses
are considered.
7.3.2 Multiple testing correction
The estimated graphical source set DˆG is a random variable, and its sampling properties
hinge on the employed likelihood ratio test. In particular, there are k asymptotically
independent tests within each decomposition of the global hypothesis. If we control the
family-wise error rate (FWER) at a level α, when there are no diferences between the
two conditions (i.e., under the null hypothesis) DˆG will be an empty set with proba-
bility converging to (1−α). We are thus protected against the inclusion of false positives.
The described procedure performs a total collection of m tests, of which k are
marginal and
√k
i=1 v(Ci) are conditional tests, where
√k
i=1 v(Ci) denote the number of
unique separators contained within the k cliques. While the p-values corresponding to
hypothesis within each ordering are independent, this is not true for p-value across
decompositions, and this deĄnitely calls for multiple testing error correction.
The naive approach to control the FWER would be to apply the Bonferroni
correction but in general intricate relationships among subgroups of hypothesis lead
to high dependence on the associated p-values. Under this circumstance, Bonferroni
correction is known to be conservative, and this means that the true FWER can be
signiĄcantly lower than the chosen nominal level α.
To address this problem we use a method proposed by Westfall and Young [107],
which uses permutations to obtain the joint distribution of the p-values, and by consid-
ering their dependency system and thus attenuating the conservativeness of Bonferroni.
The procedure proposed by these authors, also called maxT, starts with the creation
of T permuted datasets and calculates the m test statistics for each of these. The
results can be arranged in a (T +1)×m matrix P , where the Ąrst row is Ąlled with the
statistics calculated on the original data, while the remaining T store the test statistics
of the permuted datasets.
Fixed a level alpha, we proceed as follows:
step 1) for each column of P , we calculate the asymptotic p-values for the hypotheses;
step 2) for each row of P , we calculate the minimum for each (T + 1) dataset;
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step 3) the corrected threshold θi is the α-quantile of the permutational distribution
of the p-values obtained in the previous step.
To get a threshold as close as possible to α, we decided to use a step-down version
of the algorithm. Then, at the end of the three steps, we remove from the matrix P all
the columns associated with rejected tests using the corrected threshold θi. Steps (2)
and (3) are repeated on the resized P matrix until no hypothesis is rejected, considering
the θi threshold for each i-th iteration.
As described in the previous paragraph (Section 7.3.1), if a regularized estimate of
the covariance matrix is used, asymptotic distribution is no longer valid, and the minP
version must be used. In this case, we compute permutational p-values per-hypothesis
to obtain the P˜ matrix, where each p˜i,j elements is deĄned as #¶l : pl,j ≤ pij♢. The
matrix P˜ replaces the P matrix in the maxT algorithm.
The number T of permutations is always an issue with permutation-based mul-
tiple testing. It depends on the method, the alpha level chosen, and the number of
hypotheses m. Although it would be best always to use the collection of all possible
permutations, this is computationally not feasible even for a moderate dataset. For
this reason, a collection of randomly generated permutations is often used.
The minP method usually requires more permutations than maxT , due to the
discrete nature of the permutation p-values. In fact, the minimum observed p-value will
be equal to the minimum possible p-value for most of the permuted datasets - unless
the number of permutations is very large - resulting in zero power for the method.
For this reason, Goeamann et al. [35] recommend using m/α permutations as an
absolute minimum. For maxT the authors ensure appreciable performance with only
1/α permutations when these can be enumerated. While with random permutations a
higher number is suggested: 1.000 permutations are suicient when the threshold is set
at 0.05.
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7.4 Appendix: lexicon and notation
Here, we brieĆy review key notions regarding Gaussian graphical models, relevant for
our work.
Consider an undirected graph G = (V,E) where V is a set of nodes and E is a set
of edges. A subset of vertices A deĄnes an induced subgraph GA = (A,E ∩ A×A). A
clique is a maximal complete subgraph, that is, it is not a subset of any other complete
subgraph. Two disjoint subsets A,B ∈ V are said to be separated by a subset S
(disjoint from A and B) if all paths from A to B contain vertices from S.
A graph G is decomposable if and only if the set of cliques of G can be ordered so
as to satisfy the running intersection property, that is, for every i = 2, ..., k:
if Si = Ci ∩
i−1⋃
j=1
Cj then Si ∈ Cl for some l < i− 1
although this ordering is generally not unique, the structure of the graph G uniquely
determines the set of cliques ¶C1, ..., Ck♢ and the set of separators ¶S2, ..., Sk♢. For ease
of notation, it is often set S1 = ¶∅♢, so that the set of separators become ¶S1, ..., Sk♢.
For simplicity, we consider only graph consisting of a simple connected component,
although most of the presented notions remain valid for more general graphs. We
also restrict our attention to decomposable graphs, and this assumption is central
to our approach. We assume throughout that cliques have been ordered in an order
satisfying the running intersection property. Since, we deal with diferent partitions of
the set of vertices, we note that such an ordering naturally leads to several partitions
of V . Recall that (A, S,B) is said to be a partition of V if A, S and B are disjoint
and V = A ∪ S ∪B. Partitions of V that correspond to decompositions of the graph
G are of particular interest. For a graph G = (V,E), a partition (A, S,B) of V is a
decomposition of G if A and B are separated by S in G, and S is complete.
Denote p = ♣V ♣ and let X ∼ N (µ,Σ) be a p-variate norm vector indexed by vertices
of G. If Σ is invertible and such that its inverse, K = Σ−1, has zeroes corresponding to
missing edges of G we say that X is a Gaussian graphical model. Let S+ denote the set
of all symmetric p×p positive deĄnite matrices with zeros corresponding to the missing
edges of G. Moreover, for A ⊂ V , let ΣA denote the corresponding block submatrix of
Σ. In gaussian graphical models, decompositions of the graph G correspond to special
properties of the induced statistical models and associated inference procedures (see,
Djordjilovic et al. [23]).
Chapter 8
IMPLEMENTATION
The programming language and style used for implementation play an important role
in the difusion of a method. Many of the developed GSEA approaches are imple-
mented in R programming language [96] and are available as software packages either
from Bioconductor and CRAN repositories, or the authorŠs website. Their popularity
depends not only on their usefulness but also on their availability as R package and
their maintenance [67].
For this reason, the presented method (Section 7.2) has been implemented in an R
package, called SourceSet (soon available on one of the above-reported repositories).
In particular, the model has been extended to Ąt into the more traditional PA framework,
where the interest is in considering more than one pathway at a time.
Thus, the functions contained in the package:
(i) use a list of pathways and a matrix of values that represents the gene expressions,
to identify - for each graph - a set of variables consisting of potential sources of
diferential behavior between two experimental conditions;
(ii) perform a global meta-analysis on the entire set of input pathways, to provide
replicable summaries of research Ąndings through additional visualization tools
and statistics.
Although our focus is on gene set analysis, it should be stressed that the developed
methodology and its R packages are readily applicable in a wide range of other contexts.
More precisely, it suits situations where the graphical structure is given a priori and
remains constant across to two experimental conditions - allowing only the strength
of relations between variables to change - and whenever the data can be assumed to
be Gaussian. In the biological context, this includes, among others, log-transformed
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microarray gene expression data, squared root reads counts or RPKM/FPKM in
next-generation sequencing experiments and protein abundance.
In the following (Section 8.1), we present the algorithm in detail, with some notes
on the extension to the case of N pathways and the issues discussed in (Section 7.3).
A basic introduction to the usage of the package and its features, with particular
emphasis on meta-analysis and personalization of graphical display of results, is given
in (Section 8.2).
8.1 Algorithm
Motivated by the diferential analysis of gene expression data, we proposed a method
for identifying the set of genes responsible for the diference between two multivariate
normal distributions Markov with respect to the same pathway.
Given a graph G - representing the dependency structure encoded in a pathway
- and a matrix of values - that contains the expression levels of the measured genes
in the collected samples for two experimental conditions - a general scheme of the
procedure can be outlined as follows (Figure 8.1):
(step 1) decompose graph G in the set of the maximal cliques and the set of separators.
Gmust be decomposable, so it may be necessary to moralize and/or triangulate
the starting graph.
(step 2) identify the cliques orderings, and the associated separators, that satisfy the
running intersection property, using each clique as root.
(step 3) (a) calculate marginal test statistics for the cliques and the separators, for
both the original and the permutated datasets;
(b) compute the conditional test statistics for the unique components, cal-
culated as the diference between clique and separator marginal test
statistics;
(c) correct the α level to control the FWER, using the test statistics matrix
of the previous point.
(step 4) make the union of the sets of variables belonging to cliques that are associated
with a signiĄcant test, for each ordering deĄned in (step 2).
(step 5) derive the source set, deĄned as the intersection of the set of variables obtained
in (step 4).
8.1 Algorithm 67
Fig. 8.1 Basic outline of sourceSet algorithm for the analysis of a single graph.
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Looking at the broad picture of the N pathways case, to make the procedure
consistent some major clariĄcations have to be made. In the following, we point out
some computational remarks about the basic outline.
(Note 1 ) List of pathways
The primary interest of our work is not in the detection of the structure of a pathway
because we consider it as Ąxed a priori. Various research groups have tried diferent
strategies to address this challenge that has led to the development of many knowledge
databases. To incorporate pathways into graphical models, the diagram needs to
be translated into a mathematical graph, either directed or undirected. Due to the
descriptive nature of pathways and their inherent complexity, there is no simple recipe
for conversion that can be applied in every situation. For this reason, close collaboration
with biologists is preferred at this step [24].
In general, we give full freedom to the user in providing the underlying graph,
constraining only to accept a speciĄc input data format (i.e., a graphNEL object). So,
the user can provide a list of manually curated pathways, or use developed software to
translate the bases of knowledge. To date, the most complete software available for
this task is graphite R package [84]. graphite provides easy access to six diferent
databases for a total of 14 diferent species. The resulting networks represent a uniform
resource for the pathway analysis.
Regardless of the type of graph, obtained at the end of the translation (i.e., undi-
rected or directed), our method works only with decomposable structure. However, it
should be stressed that starting from a valid graph we can always obtain a decomposable
one in a few steps (i.e., moralization and triangulation).
(Note 2 ) Setting the parameters
The input pathways normally have heterogeneous size and degrees of connectivity. To
make the results obtained from each graph comparable, and to conduct a meta-analysis,
particular attention is needed for the choice of the parameters. In particular, two
parameters have to be set:
• the estimation method for the covariance matrices, i.e., sample or regularized;
• the number of permutations for the multiple testing threshold correction.
The estimation method must be the same for all pathways. If the user wants
to use the sample covariance matrix, all cliques - in all pathways - must satisfy the
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n > pi condition, where n is the number of samples for the smallest class and pi the
cardinality of the largest clique in the i-th pathway. If even one clique does not satisfy
this requirement, the regularized estimate must be used. To obtain a reliable power,
for the sample covariance estimate, it is recommended to use as criterion n≫ pi (see
Section 9.1.3). Indeed, the distribution used to calculate the p-values of the performed
tests is only asymptotically valid.
The number of permutations Ti, whether itŠs the maxT or minP correction, is
naturally suggested from the α threshold and the number mi of unique tests in the
i-th pathway (see Section 7.3.2). Using diferent thresholds allows us to simultaneously
control the ŞlocalŤ FWER and achieve comparable power among graphs. A ŞglobalŤ
FWER control is possible by using a single (TM + 1)×M matrix P, where M is the
number of unique tests performed in each pathway, that is M =
√N
i=1mi. The main
problem is that the number of TM permutations is generally very large, making the
algorithm computationally onerous. Besides, the results may be lost reproducibility as
the threshold - and the power - depends on the number and the degree of connectivity
of the input graphs. For these reasons, the ŞglobalŤ option is not considered in the
implemented algorithm.
(Step 1-2 ) Decomposition and orderings
For each path, the Ąrst step requires identifying the maximal cliques and all possi-
ble decompositions of the global distribution induced by the decomposable graph G.
Generally speaking, the clique problem is NP-complete, indeed it is Ąxed-parameter
intractable and hard to approximate. Listing all the maximal cliques can take an
exponential time. Therefore, much of the theory about the clique problem is devoted
to identifying appropriate types of graph that admit more eicient algorithms. In our
model, a consistent computational relief is possible because of decomposable graphs -
also called chordal graphs - fall into this last category. Also, the detection of permissible
decompositions is closely related to the identiĄcation of perfect orderings, and such as
problem may be solved in polynomial time when the input is chordal.
SpeciĄcally, we decided to use the rip function implemented in the gRbase package
[22]. It identiĄes a sequence of the set of cliques that satisĄes the running intersection
property by Ąrst ordering variables by the maximum cardinality search algorithm. The
root argument is used to check which clique will be the Ąrst to enter in the rip ordering.
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Function Description
sourceSet Main function
infoSource Resume informations about graphs and variables
easyLookSource Summarise the results through a ggplot
sourceSankeyDiagram Create a D3 Javascript Sankey diagram
Table 8.1 SourceSet main functions
In the ripAllRootsClique function (implemented in the SourceSet package) we
extended the search space to get all possible orderings, that is, using as root all maximal
cliques induced by the graph G. Given a graph, the function will provide:
• a list of elements: consisting of k maximal cliques and the associated k separators,
and the m unique components;
• a list of k orderings: each of them will contain a proper subset k of the m unique
components.
8.2 SourceSet R package
The SourceSet package consists principally of four functions (Table 8.1): the Ąrst
one, which is the main function, implements the algorithm seen in the previous section,
while, the other three functions guide the user in interpreting the obtained results
through a meta-analysis, providing additional statistics and graphical device.
The following sections describe the arguments required for the use of each function,
and the outputs provided.
8.2.1 Main function
LetŠs start exploring the package through the sourceSet main function. The function
necessarily requires the following arguments:
graphs a list of graphNEL objects, that represent the pathways to be
analyzed.
data a matrix of expression levels with column names for genes and row
names for samples.
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classes a vector of 1 and 2 indicating the classes of samples. This vector
must be matched with the rows of the data matrix, and can not
contain more than two classes.
alpha the p-value threshold
shrink if set to TRUE , the algorithm will use the regularized estimate of
the covariance matrices; otherwise, it will use the sample covariance
matrices.
permute if set to TRUE , permutational p-values will be computed for the
signiĄcance of the tests; otherwise, the asymptotic distribution will
be used.
If the last two parameters violate the assumptions required for the existence of the
source set estimate (Section 7.3.1), the algorithm reserves the possibility to change the
user settings through internal controls. A progress bar will show, for each pathway,
the permutations status and the elapsed time.
The output of the main function is an object of the sourceSetList class. It
contains as many lists as the input graphs, and provides the following variables:
sourceSet a vector that contains the name variables belonging to the
estimated source set DˆG
marginalSet a list of vectors, one for each ordering, that contain the
name variables belonging to the estimated source set DˆG,i
Components a data frame that contains all the information about the m
unique conditioned tests of the form Ci \ Si♣Si, including
the associated p-values
Decompositions a list of data frame, one for each identiĄed ordering. Each
data frame is a subset of size k, of the Components elements
Elements all the sets of cliques and separators induced by the used
decomposable graph (see Graph)
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Threshold a list that contains all information regarding the threshold
correction for multiple testings. It includes:
• alpha : the input threshold;
• value : the corrected threshold;
• type : the used procedure (minP or maxT );
• iterations : the number of iterations for the step-down
procedure;
• nperms : the number of T permutations.
Graph the used decomposable graph. It should be pointed out
that it may not be the same as the input graph. In fact, if
it is not decomposable, the function will internally provide
to moralize and triangulate it.
8.2.2 Meta-analysis and visualization
Although the interpretation of the source set for a single graph is intuitive, the analysis
of the whole collections of results obtained from the N pathways might be complex.
For this reason, we propose a guideline for the meta-analysis providing descriptive
statistics and predeĄned plots. The key input argument of the meta-analysis functions
is an object of the sourceSetList class, that is the output of the sourceSet function.
Additional parameters may be needed to customize the display.
infoSource
The infoSource provides a summary of the results by focusing on either nodes or
pathways, in fact, it supplies two diferent lists that are composed as follows:
$graph
n.source number of genes belonging to the source set, that is ♣DˆG♣
n.marginal number of genes belonging to at least one of the ordering
source set, that is ♣
√k
i=1 DˆGi♣
n.graph number of genes in the graph, that is ♣V ♣
n.cluster number of disconnected graph in G
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source.impact percentage of genes in the source set compared to the total
genes in the graph. This index quantiĄes the proportion of
the graph impacted by the primary dysregulation.
marginal.impact percentage of genes in at least one of the ordering source
set compared to the total genes in the graph. This index
quantiĄes the proportion of the graph impacted by the
secondary disregulation
p.value mean of the k p-values obtained for each ordering by the
FisherŠs method combination of the k independent p-values.
$variable
n.graph number of pathways in which the gene is contained.
specificity percentage of pathways in which the gene appears, compared
to the total number of analyzed pathways.
source.impact percentage of time in which the gene is in the source sets,
compared to the total number of pathways in which it
appears.
marginal.impact percentage of time in which the gene is in at least one order-
ing source sets, compared to the total number of pathways
in which it appears.
relevance percentage of times in which the gene is in the source sets,
compared to the total number of analyzed pathways. From
a general measure of the importance of the node based on
the chosen pathways.
score logarithm of the mean of the scores for the gene in all
analyzed pathways changed in sign. The lower bound is
zero (i.e., no signiĄcance), while the upper bound is +∞
(i.e., maximum signiĄcance). The score depends on the
p-values of the Hi,j tests calculated in all orderings of the
input pathways.
Formally, it is defined as − log(
√P
p=1
scorexp/P ), for p = 1, .., P , where P is the
number of pathways and x is the considered gene. Instead, scorexp = max(p
x
i,j
)
for i = 1, ..kp, where pxi is the p-value for the j-th component in the i-th ordering,
such that Ci,j/Si,j contains x.
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easyLookSource
The function easyLookSource allows to summarize the results of the analysis through
an heatmap (Figure 8.2b). The plot is composed of a matrix in which, on the rows,
are represented the pathways and, on the columns, the genes.
Each celli,j can take one of the following conĄgurations:
(2) blue color, if the i-th gene is in the source set of the j-th pathway;
(1) light blue color, if the i-th gene is in at least one of the ordering source set of the
j-th pathway;
(0) gray, if the i-th gene belong to the j-th pathway;
(NA) white, if the i-th gene does not belong to the j-th pathway.
In the plot, the pathways are vertically ordered - top to bottom - according to the
numbers of nodes in the source set. Instead, genes are horizontally ordered (from left
to right) based on the number of times they appear in a source set.
sourceSankeyDiagram
Another way to summarize the results in a visual manner is through a Sankey diagram
(Figure 8.2c). It allows to highlight the relationships among nodes, graphs, and source
sets.
The layout is organized on three levels:
• the Ąrst level (on the left) consists of nodes that appear in at least one of the N
source set.
• the second level (central) is made up of modules (Figure 8.2a). A module is
deĄned as a set of nodes belonging to a connected subgraph of one pathway, that
is also contained in associated source set. A pathway can have multiple modules,
and at the same time, one module can be contained in multiple pathways.
• the third level (on the right) consists of pathways.
A link between two elements a and b must be interpreted - from left to right - as
Şelement a is contained in element bŤ.
The implementation of the sourceSankeyDiagram function takes advantage of
the D3 library [9, 1] (JavaScript), making the plot interactive. In fact, it is possible to
vertically shift the displayed elements, and to view some usefull information positioning
the cursor over items and links .
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(a) Unique modules
(b) easyLookSource function
(c) sourceSankeyDiagram function
Fig. 8.2 Visualization of the results obtained from the sourceSet analysis, on an example database
consisting of three pathways and twenty genes. For each graph, the modules are identified on the
basis of the estimated source set (Figure 8.2a). The modules that are unique sets are used in
the representation of the interactive Sankey graph (Figure 8.2c). The easylookSource graph is
depicted in Figure 8.2b. The heat map highlights which sets the nodes belong to, in a specific pathway.
For example, the gene 7 is in the source set of the GC graph (blue rectangle) and in the marginal set
of the GA graph (light blue rectangle). The gene 10 is contained in both the GA and GB graphs, but
never appears in either the source and the marginal sets (gray rectangles); while it does not appear in
the GC graph (white rectangle).

Chapter 9
VALIDATION
9.1 Simulated data
In the context of exploratory analysis, you may be concerned about the so-called
screening property of the procedure, that is the guarantee of covering the source set
with a high probability. For our procedure, the asymptotic guarantee is given by the
consistency of the log-likelihood criterion test [23]. In the Ąnite case, this property is
closely related to the power of the underlying test and the magnitude of the diferences
between the two conditions.
We then studied the properties of the proposed method with a simulation study,
both under the null hypothesis and under the alternative hypothesis. In the Ąrst part
(Section 9.1.1), we illustrate some critical points about in silico data generation from
biological networks, and brieĆy outline the proposed strategy. In the last sections, we
describe the simulation settings (Section 9.1.2) and the results obtained (Section 9.1.3).
9.1.1 simPATHy package
Generating synthetic data that mimics the real biological dysregulation and that can
be used as a benchmark dataset should be the Ąrst step of a proper validation strategy
for any GSA tools. Nevertheless, almost all the methods proposed so far limited their
attention to verifying performance under the null hypothesis of equality between the
two populations, where the simulation strategy is trivial (i.e., the random sample of
group labels).
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Fig. 9.1 Shiny app allowing for an interacting exploration of the simPATHy output.
Creating synthetic data from two experimental conditions that difer only for a
subset of genes that represent primary genes and emulate signal propagation following
the topology of a pathway is not a simple task. In fact, to the best of our knowledge,
there were no tools that simulate data according to this design.
For this reason, during my Ph.D. I have worked on the development of a new
method for simulating data from perturbed biological pathways based on probabilistic
graphical models. simPATHy is implemented in an R package and freely available
on CRAN. In this framework, we assume to model the data of the same pathway in
diferent experimental conditions through two undirected graphical models that share
the same structure G.
The model assumes that the disregulation mechanism is the efect of a set of genes,
and as a consequence of this perturbation it propagates on the remaining variables
through the connections described in the structure of a pathway. Intuitively, the idea
is to emulate a chain of reactions.
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Given a set of primary genes d and a subset of edges e - contained in the induced
subgraph of the genes in d - the model deĄnes a perturbation in three diferent ways:
• a change in the force of the connections in e (i.e., the pairwise covariances);
• a change in the variability of the genes in d (i.e., the variances);
• a change in the expression levels of the genes in d (i.e., the means).
Containing the covariance matrix all the information on the pathway topology, this
is the key element on which simPATHy works.
The algorithm is able to:
(i) obtain an estimate of a covariance matrix compatible with a given graph starting
from a sample covariance matrix;
(ii) modify the strength of selected variances/covariances elements that emulate the
signal perturbation;
(iii) provide an appropriate repair mechanism based on the spectral decomposition of
the correlation matrix for indeĄnite matrices.
In fact, even small changes to the covariance matrix elements result in an indeĄnite
matrix and a lost of the structure of G in the corresponding concentration matrix.
Adjusting the mean, however, consists in just decreasing/increasing the original values.
The covariance matrix and the vector of the starting mean (i) represent the pa-
rameters of the reference condition; while the modiĄed covariance matrix (iii) and the
vector of the - eventually - changed means represent the parameters of the perturbed
condition. These parameters are used to generate random samples from normal mul-
tivariate distributions. Formally, starting from the parameters related to the control
group, the procedure act on means, variances, and covariances so that the conditional
distribution of the variables on which it doesnŠt intervene remains unchanged under
the two conditions. However, this action afects the entire global joint distribution,
thus creating the propagation efect.
For more technical details, please refer to the original work [85], while referring to
the R package vignettes for instructions on the software.
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Fig. 9.2 Decomposable graph G consisting of 10 nodes, 5 cliques and 13 unique components.
9.1.2 Settings
We studied the Ąnite case behavior of our algorithm through a simulation study under
diferent scenarios, following the algorithm described in the previous paragraphs. To
better understand the results of the simulation, we assumed that the dysregulation
mechanism directly afects only a single gene, so we considered the perturbation deĄned
as under (ii) and (iii), i.e., as an increase of the mean and the variance parameters of
the chosen gene.
We used an a priori Ąxed graph G (Figure 9.2) and we considered three diferent
scenarios:
(scenario 1) there are no differences between the two conditions: the source set is the
empty set and so we are under the null hypothesis, D = ¶∅♢;
(scenario 2) the differences between the two conditions are driven by a node that is
a separator within the graph G: the real source set is the variable X5,
D = ¶5♢;
(scenario 3) the differences between the two conditions are driven by a node that is
contained in only a clique of the graph G: the real source set is variable
X10, D = ¶10♢.
For the last two scenarios, which are under the alternative hypothesis, the pertur-
bation may be due to mild, moderate or strong intervention. It implies an increase in
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the mean and the variance parameters of 20%, 60%, and 100%, respectively.
To verify the power of our procedure when we move away from the asymptotic
distribution, we considered several numbers of samples for each class (n = n1 =
n2 ∈ ¶25, 10, 5♢). Since the cardinality of the largest clique is 4 (case n > p), the
sample covariance matrix is well deĄned so we can use both the standard and the
regularized approach. To observe the power of the two estimator methods, we rely on
the permutational p-values corrected with the step-down minP algorithm with α equal
to 0.05 and a number of permutation T set to 1.000 (T ≫ m/α = 260).
For each combination of source set and disregulation intensity, we obtained the
mean and the variance parameters for the two conditions as described in Section 9.1.1.
The parameters are used to generate 500 datasets derived from multivariate normal
multivariate, for each number of samples. All the parameters used in this simulation can
be found in the SourceSet package, through the data(simulation) command.
To evaluate the performance of our procedure, we considered the power of the test,
deĄned as the number of times that the estimated source set DˆG is contained in the
true minimal source set D.
9.1.3 Results
H0: Null hypothesis
Under the null hypothesis, the algorithm demonstrates an excellent control of Type
I error (Table 9.1) regardless of sample size and the choice of covariance matrix
estimation method. Note that the procedure seems very conservative under the global
null hypothesis. This behavior can be explained by the fact that when there are no
diferences between the two conditions, at least two false rejections are needed in order
to obtain a non-empty source set estimate. This is, however, characteristic only for the
global null hypothesis: when among considered hypotheses some are false, the control
of the FWER is more accurate.
H1: Alternative hypotesis
The results under the alternative hypothesis, for the sample covariance estimated (left
panel) and the regularized one (right panel), are shown in (Figure 9.3). Each small
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(a) D = ¶X5♢
(b) D = ¶X10♢
Fig. 9.3 Simulation study results under the alternative hypothesis, when the true source of the
perturbation is the separator node 5 (Figure 9.3a) and the non-separator node 10 (Figure 9.3b),
for the graph shown in Figure 9.2. In the left panels, the results for the sample covariance matrix
estimate, while in the right panels, the results for the regularized estimate. Each small panel represents
a combination of the parameters (number of samples and intensity of disregulation). Each bar is
proportional to the number of times that the node appear in the source set (red bar), marginal set
(orange bar), otherwise (green bar).
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D = ¶∅♢ sample covariance matrix regularized covariance matrix
n = 25 0.004 0.008
n = 10 0.008 0.022
n = 5 0.022 0.012
Table 9.1 Type I error for simulated data for different sample sizes (n = n1 = n2) and
different estimators for the covariance matrix.
panel represents a conĄguration of the parameters (intensity and number of samples).
Within them, there are three colored bars for each node:
• the red bar is proportional to the number of times the node d appears in the
estimated source set, d ∈ DˆG;
• the orange bar is proportional to the number of times the node d is in the
estimated source set of at least one ordering but not in all, ∃i such that d ∈ DˆG,i
but d /∈ DˆG;
• the green bar in the remaining case.
The length of each bar is 500, that is the number of simulated datasets.
Not surprisingly, the results depend on the setting used in the scenario. If we
consider the scenario 2 where D = ¶5♢, when the intervention is moderate or strong,
and the sampling number is n ≥ 10, the power is equal to 1 in all the considered
cases. On the other hand, when the number of samples is close to the theoretical limit
for the existence of the LLR criterion (i.e., 5), the regularized estimator outperform
and correctly identiĄes the source set about 80% of the times compared to the 13%
reached by the sample covariance matrix estimator. When the intervention is mild,
the performances are lower for both the approaches, although the improvement that is
obtained through the stabilization operation remains.
All the above considerations can be extended to the scenario 3, where the true
source set is a non-separator node. In this case, however, a remark is mandatory.
While for the second scenario the DˆG corresponds exactly to D, in the third DˆG only
contains D. In fact, as anticipated (Section 7.2.4), our estimator tests the subsets
of hypotheses that are induced by the structure of G, and hence it is not necessarily
minimal. However, this behavior should not be considered as a false positive in our
simulation. Moreover, if we consider the biological context, this behaviour should not
be a cause for concern, in fact, i) pathways are represented by undirected decomposable
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graphs that are - often - very connected, and therefore most nodes are separators; (ii)
highly connected genes (hub genes) are more likely to be the cause of the disease as it
has been shown to be the most lethal.
Finally, although the used graphical model is simple and the perturbation restricted
to one node at a time, we are conĄdent that the conclusions can be extended to more
complex models and scenarios, including the n≪ p case.
9.2 Biological validation
The goal of classical TPA methods is to identify the most perturbed pathway in a given
experimental condition. As, to date, there is no universally accepted technique for the
validation of the results, it is common practice to select one (or more) dataset such
that there is a speciĄc pathway that model the investigated condition. For example,
breast cancer pathway in KEGG will be the target pathway in a breast cancer dataset.
Analyzing and ranking all (or a subset) pathways, according to the score provided by
the method, it is expected that the target will be as high as possible.
Intuitively, a pathway should be more signiĄcantly impacted if it hosts several genes
that are the real source of perturbation [3]. But, as we pointed out in Section 7.2.1, most
of the currently available methods cannot distinguish between primary and secondary
disregulation. As a result of the complexity of biological phenomena, a large num-
ber of pathways are virtually implicated in all conditions leading to a bias in the results.
Although the objective of the proposed method is diferent (i.e., identifying genes
responsible for the perturbation, and not the most perturbed pathways), we can use a
similar validation technique, with a focus on genes. Moreover, we can illustrate how a
marginal approach can hide the role of primary genes. For this reason, the assessment
will focus on the ability of the source set algorithm to identify genes that are involved -
or for which there are documented evidence - in the origin of phenotypes under study.
In particular, two validation approaches are used.
The Ąrst dataset (Section 9.2.1) refers to the knock-down of STAT3 gene in patients
afected by High-Grade Glioma. In this experiment, the exact source of perturbation
is known, that is, the speciĄc gene that has been knock-down. For this reason, all
pathways that include this gene will be selected for validation, and STAT3 gene will
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be expected to be included in the source set of each graph.
In the second approach (Section 9.2.2), we consider a well-known benchmark dataset
on the ABL/BCR Acute Leukemia Lymphocytic (ALL) chimera, already analyzed by
many other authors [3, 13, 27, 61, 62]. Although - unlike knock-down experiments -
there is no true source of disregulation, some genotype abnormalities are known to be
responsible for diferent transformation mechanisms of ALL and, as a consequence,
of diferent response to treatment. Comparing patients with and without the B-cell
receptor (ABL/BCR) gene rearrangement and analyzing all available pathways, we
expect that the genes of the chimera will be present in the source set of the pathways
that contained them. Moreover, we foresee that the chimera genes result among the
most relevant genes in the meta-analysis. In this disease, the target pathway is Chronic
Myeloid Leukemia.
To derive the list of underlying pathways needed as input for the sourceSet
function, we used the graphite R package [84], which transforms the pathways
contained in KEGG database [47] into graph objects. Each of these objects has been
moralized and triangularized to obtain decomposable graphs (gRbase package [22]).
The number associated with each node is a unique gene identiĄer from the Entrez Gene
database at National Center for Biotechnology Information [58].
In the next sections, we present the results of these two case studies.
9.2.1 Silencing of STAT3 in brain tumors
The High-Grade Glioma (HGG) is the most common brain tumor in humans. Despite
multimodal treatment with surgery, radiotherapy, and chemotherapy, these patients
cannot be cured. The median survival of patients with glioblastoma (GBM) - the most
frequent and malignant HGG - is only 15 months.
It is known that the over-expression of a mesenchymal gene expression signatures
(MGSE) is associated with a poor prognosis in glioma patients. Carro et al. [12]
identiĄed 6 TFs that controlled the expression of > 74% of the MGSE genes. Two
of them (STAT3 and C/EBPβ) emerge as synergistic initiators and master regula-
tors (MRs) of this speciĄc cancer signatures. To further investigate the role of both
the TFs, the authors silence STAT3 and CREB both independently, and in combination.
Here we report the analysis of only STAT3 silencing dataset. The dataset includes
22 samples (11 knockdown and 11 control patients) and 19.292 measured gene expres-
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Fig. 9.4 easyLookSource visualization of the source set analysis results for STAT3 dataset. All
the KEGG pathways that contained the STAT3 genes (nG = 17) and the genes that appeared in
at least one source set, are represented. The number associated with each node is a unique gene
identifier from the Entrez Gene database. In particular, the STAT3 gene has the Entrez ID 6774. A
gene (column) can be in the source set (blue rectangle), in the marginal set (light blue rectangle) of a
pathway (row), or otherwise (gray rectangle). If the gene is not present in a pathway, the rectangle is
white.
sion levels. The original dataset is available in the GEO database, with the accession
number GSE19114.
A total of 17 biological pathways from KEGG contain STAT3 gene (Table 9.2a).
The analysis has been performed only on these pathways to validate the performance
of our method to identify the primary dysregulation. The number of DEG (using
Empirical Bayes test as implemented in limma package with FDR < 0.05) is 1.029,
and as expected, STAT3 is the most diferentially expressed. Forty out of 1.029 DEGs
are mapped to the 17 biological pathways considered.
Using our method we identify all pathways with STAT3 as signiĄcant. In particular,
looking at Figure 9.4, it is worth to note that, apart from Pathway in Cancer, STAT3
is always included in the source set. Indeed, it has been found on 16 over 17 pathway
(source.impact=0.941). We highlight that in four out of 16 pathways (Table 9.2b),
STAT3 is the only element of the source set, although marginal regulation involves
many more genes. Th17 cell differentation pathway gives the most obvious example:
the source set algorithm identiĄes STAT3 as the primary source of disregulation while
classifying the remaining 39 genes as perturbed by the efect of signal propagation (i.e.,
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(a) General pathways information
Name ♣V ♣ ♣E♣ n.cluster k max(♣Ck♣) ♣DEG♣
Acute myeloid leukemia 55 193 1 30 11 4
Adipocytokine signaling pathway 62 286 1 39 11 4
AGE-RAGE signaling pathway in diabetic complications 87 582 2 43 17 8
EGFR tyrosine kinase inhibitor resistance 79 468 1 33 19 6
Epstein-Barr virus infection 81 268 7 38 11 7
Hepatitis B 129 597 4 69 17 11
HIF-1 signaling pathway 97 459 1 61 13 8
Inflammatory bowel disease (IBD) 47 131 1 30 7 2
Insulin resistance 91 675 1 32 17 10
Measles 99 375 9 41 15 4
Non-small cell lung cancer 56 228 2 23 10 4
Pancreatic cancer 62 233 4 31 13 6
Pathways in cancer 304 2878 3 131 28 22
Prolactin signaling pathway 70 404 1 31 13 3
Signaling pathways regulating pluripotency of stem cells 107 751 1 37 28 6
Th17 cell differentiation 90 650 2 36 20 5
Toxoplasmosis 87 259 6 41 13 6
(b) Results of source set analysis
Name n.graph n.source n.marginal
source
impact
marginal
impact
p-value
Acute myeloid leukemia 55 5 13 0.091 0.236 ≈ 0
Adipocytokine signaling pathway 62 1 29 0.016 0.468 ≈ 0
AGE-RAGE signaling pathway. . . 87 1 15 0.011 0.172 ≈ 0
EGFR tyrosine kinase inhibitor. . . 79 6 19 0.076 0.241 ≈ 0
Epstein-Barr virus infection 81 8 22 0.099 0.272 ≈ 0
Hepatitis B 129 8 12 0.062 0.093 ≈ 0
HIF-1 signaling pathway 97 7 19 0.072 0.196 ≈ 0
Inflammatory bowel disease 47 3 12 0.064 0.255 8.30e−06
Insulin resistance 91 3 21 0.033 0.231 ≈ 0
Measles 99 3 3 0.030 0.030 ≈ 0
Non-small cell lung cancer 56 2 2 0.036 0.036 ≈ 0
Pancreatic cancer 62 5 18 0.081 0.290 ≈ 0
Pathways in cancer 304 0 9 0.000 0.030 ≈ 0
Prolactin signaling pathway 70 4 39 0.057 0.557 7.94e−05
Signaling pathways regulating. . . 107 1 7 0.009 0.065 ≈ 0
Th17 cell differentiation 90 1 40 0.011 0.444 1.00e−07
Toxoplasmosis 87 3 7 0.034 0.080 ≈ 0
Table 9.2 Pathways meta-analysis results for STAT3 dataset, provided by infoSource
function. Pathway where STAT3 gene is the only element of the source set are highlighted.
For more details about the interpretation of each index, see table $graph in Section 8.2.2 .
Entrez Symbol n.graph specificity
source
impact
marginal
impact
score relevance
6774 STAT3 17 1.00 0.94 1.00 7.07 0.94
3716 JAK1 9 0.53 0.56 0.90 0.51 0.30
6772 STAT1 9 0.53 0.22 0.44 0.85 0.12
6776 STAT5A 8 0.47 0.25 0.25 2.11 0.12
6777 STAT5B 8 0.47 0.25 0.25 1.72 0.12
6198 RPS6KB1 4 0.24 0.75 1.00 1.82 0.18
1019 CDK4 4 0.24 0.50 0.50 2.39 0.12
1021 CDK6 4 0.24 0.50 0.50 2.39 0.12
6199 RPS6KB2 4 0.24 0.50 0.75 1.71 0.12
Table 9.3 Genes meta-analysis results for STAT3 dataset, provided by infoSource function.
Knock-down gene is highlighted. For more details about the interpretation of each index, see
table $variable in Section 8.2.2.
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(a) General pathways information
Name ♣V ♣ ♣E♣ n.cluster k max(♣Ck♣) ♣DEG♣
Axon guidance 126 793 3 66 18 2
Cell cycle 111 1024 1 35 21 3
Chronic myeloid leukemia 67 256 3 27 14 2
ErbB signaling pathway 78 294 1 43 10 2
Neurotrophin signaling pathway 98 509 2 52 13 3
Pathways in cancer 263 1960 4 127 24 5
Ras signaling pathway 170 1924 2 70 50 4
(b) Results of the source set analysis
Name n.graph n.source n.marginal
source
impact
marginal
impact
p-value
Axon guidance 126 0 49 0 0.39 0
Cell cycle 111 16 30 0.14 0.27 0
Chronic myeloid leukemia 67 2 18 0.03 0.27 0
ErbB signaling pathway 78 3 8 0.04 0.10 0
Neurotrophin signaling pathway 98 4 15 0.04 0.15 0
Pathways in cancer 263 3 61 0.01 0.23 0
Ras signaling pathway 170 2 4 0.01 0.02 0
Table 9.4 Pathways meta-analysis results for ALL dataset, provided by infoSource
function. Only pathways that contain chimera genes are shown. Pathways that contain
both chimera genes in the estimated source set are highlighted. For more details about the
interpretation of each index, see table $graph in Section 8.2.2.
secondary disregulation).
In addition to STAT3, meta-analysis tools provide a panel of four other genes (Table
9.3) with attractive characteristics (high/moderate relevance and score indices): one
member of the Janus kinase family (JAK1), other members of the STAT family (STAT1,
STAT5A, STAT5B), some ribosomal proteins (RPS6KB1 and RPS6KB2) and some
cyclin-dependent kinases (CDK6, CDK4). All of these genes have direct protein-protein
interactions with the knock-down gene. As a consequence of this proximity, they could
capture the efect of primary disregulation in all those pathways where the STAT3
gene is not annotated.
9.2.2 ABL/BCR chimera in acute leukemia
Several distinct genetic mechanisms lead to ALL malignant transformations deriving
from diferent lymphoid precursor cells that have been committed to either T-lineage
or B-lineage diferentiation. In particular, chromosome translocations and molecular
rearrangements are frequent events in B-lineage ALL and reĆect distinct mechanisms
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Entrez Symbol n.graph specificity
source
impact
marginal
impact
score relevance
5330 PLCB2 37 0.25 0.24 0.62 1.90 0.06
5331 PLCB3 37 0.25 0.24 0.62 1.87 0.06
5332 PLCB4 37 0.25 0.24 0.62 1.85 0.06
23236 PLCB1 37 0.25 0.23 0.62 1.84 0.06
25 ABL1 7 0.05 0.86 1.00 7.24 0.04
217 ALDH2 6 0.04 0.83 0.83 5.81 0.03
3678 ITGA5 5 0.03 1.00 1.00 7.01 0.03
8900 CCNA1 5 0.03 0.80 1.00 6.81 0.02
857 CAV1 3 0.02 1.00 1.00 7.60 0.02
613 BCR 2 0.01 1.00 1.00 7.60 0.01
Table 9.5 Genes meta-analysis results for ALL dataset, provided by infoSource function.
Chimera genes are highlighted. For more details about the interpretation of each index, see
table $variable in Section 8.2.2.
of transformation. The relative frequencies of speciĄc molecular rearrangements difer
in children and adults with B-lineage ALL. The BCR breakpoint cluster region and
the c-abl oncogene 1 (BCR/ABL) gene rearrangement occurs in about 25% of cases in
adult ALL, and much less frequently in pediatric ALL.
The dataset we used here was published by Chiaretti et al. [14] and characterizes
gene expression signatures in acute lymphocytic leukemia cells associated with known
genotypic abnormalities in adult patients. Expression values (as available in the ALL
BioC package [56]), appropriately normalized according to robust multiarray analysis
(rma) and quantile normalization consist of n1 = 37 observations from one experimental
condition (BCR/ABL, presence of gene rearrangement) and n2 = 42 observations from
control condition (NEG, absence of rearrangement) and 8.595 genes. Using classical
inferential analysis, we found 159 DEGs (only ABL1 is present).
In this case study, we decided to perform the analysis on the whole set of KEGG
pathway (nG = 148). Given the presence of the BCR/ABL chimera we expected that
i) all pathways including BCR and/or ABL1 genes will be found as signiĄcant, and ii)
the chimera genes will be included in the source set. SpeciĄcally, we require that the
source set of Chronic myeloid leukemia (i.e., the pathway that describes the impact of
the fusion genes in the cell) would be composed only by the chimera.
On the whole set of pathways, 56 (36%) have a non-empty source set, with a median
size of four genes. The total number of genes in the source sets is 218 (Figure 9.5).
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Fig. 9.5 easyLookSource visualization of the source set analysis results for ALL dataset. All
the pathways contained in KEGG database (nG = 148), and the first 50 genes, sorted in descending
order with respect to the number of times they appear in source sets, are represented. The number
associated with each node is a unique gene identifier from the Entrez Gene database. In particular,
the chimera genes ABL1 and BCR have the Entrez ID 25 and 613, respectively. A gene (column) can
be in the source set (blue rectangle), in the marginal set (light blue rectangle) of a pathway (row), or
otherwise (gray rectangle). If the gene is not present in a pathway, the rectangle is white.
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ABL1 is annotated in seven pathways (Table 9.4a), and apart from one (Axon
guidance), it is always identiĄed in the source set (Table 9.4b). While BCR is annotated
in two pathways and for both, it is detected in the source set. It is worth noting that,
as required, ABL and BCR are the only genes in the source set of the target pathway.
In this case, the source set algorithm highlights the fundamental role of the chimera,
which with the marginal methods described in Section 7.1, would be hidden because of
the propagation of the perturbation, involving 18 out of 63 genes.
Moreover, some members of the protein family of phosphocloresters PLCB (PLCB1,
PLCB2, PLCB3, PLCB4) emerge as genes involved in several pathways of the considered
collection. However, they obtain a moderate score (score ∈ [1.84, 1.90]). Other
interesting genes are ITGA5, ALDH2, CCNA1 and CAV1 (score ∈ [5.81, 7.60]). In
particular, although CAV1 is not noted in any pathway where the ABL1 chimera
gene is present, there is evidence to support their protein-protein interaction [7].
Since CAV1 has been found to be signiĄcant in all pathways in which it is annotated
(source.impact=1 ), this gene could play a key role in capturing the efect of primary
disregulation due to ABL1 in those pathways.

Chapter 10
CONCLUSIONS
The high-throughput ŞomicsŤ technologies are providing tons of data which are growing
in size over time. The statistical analysis and the interpretation of such a complex and
dynamic biologic systems have become a major challenge nowadays.
The goal of topological pathway analysis (TPA) is to identify the most perturbed
pathways in a given condition. For this purpose, TPA methods estimate a score
for a whole pathway that represents the activation/inactivation of the corresponding
biological function. Pathways associated with signiĄcant scores are used as whole
functional units in the interpretation of phenotype association experiments.
In the perspective of identifying genes that are responsible for the diferences in a
phenotype, TPA methods fail. Indeed, they are unable to distinguish between the real
source of perturbation and the genes that merely respond to the perturbing signal.
Motivated by the analysis of diferential expression genes, we proposed to model two
experimental conditions with multivariate normal distributions with the same graph,
which represents the information encoded in a pathway. Our approach exploits the idea
of simultaneous looking at the diferences in all marginal and conditional distributions
implied by the Markov properties and uses the resulting evidence to infer the source set,
that is a set of primary genes consisting of the potential source of diferential behavior.
Moreover, the global hypothesis reformulation allows us to solve two of the main
problems that characterize omics data. Thanks to the property of interchangeability of
the observations under the null hypothesis, we improved the power of the test by a
permutational approach. Also, we made the algorithm applicable even in cases where
the number of observations is far below from the number of variables, by adopting a
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ridge strategy for estimating the covariance matrix.
Finally, we extended the algorithm to Ąt into the more traditional PA framework,
(where the interest is in considering more than one pathway at a time) and we
implemented it in the SourceSet R package. Inside, we also provided additional
statistics and graphical device to guide the user in interpreting the obtained results
through a meta-analysis.
The results for both the simulated data (obtained through simpathy , a simulation
method that we published in Bioinformatics journal [85]) and real dataset show that,
when a disregulation exist, the SourceSet algorithm leads to an excellent sensitivity
and speciĄcity in all the possible scenarios considered, even with a low number of
samples.
Although our focus is topologic pathway analysis, we feel that much of the method-
ology developed here is readily suitable for a wide range of other contexts. SpeciĄcally,
this method could be applied to the metabolome data where patients are divided into
groups according, for instance, to the presence of speciĄc polymorphisms.
Currently, this is a working progress project born during my visiting period at
Stanford University, in the Sabatti group. The study is focused on a subset of selected
SNPs that characterize diabetes, in two cohorts coming from population studies for
which are collected serum NMR-based characterization of lipoprotein and lipid measures
along with other metabolic variables.
Taking as a starting point that the metabolic network can be represented as a
graph, where metabolites and their interactions are nodes and edges, the SourceSet
model could provide the portions that are efectively associated with a group of subjects
with a particular mutation. In this way, it is possible to test groups of metabolites
within a multivariate framework and highlight only those are deregulated by a mutation.
Moreover, the SourceSet approach assumes that the graph is known a priori,
but we can relax this assumption generalizing our approach to learn the dependence
structure with an estimation procedure that uses a portion of randomly sampled data.
We are currently testing this generalization using the metabolome data.
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